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This capstone examines the root cause of the ineffectiveness of a centralized Investigational New Drug (IND)
core within a research department of a large Academic Health Center (AHC). This capstone utilized an
organizational diagnosis approach to collect data to determine what is and is not contributing to the success of
the core.
The hypotheses of this study are: 1) The centralized model was set in place without clear objectives; 2) The
IND core is not operating in the way it was structured to operate; 3) The IND core is understaffed and unable
to fully carry out the level of responsibility associated with being a Sponsor; and 4) Future expansion was not
included in the planning phase. Data was collected by interviewing staff members, and participant
observations. Prior to conducting the current state interviews, I conducted background interviews with
previous staff members to determine the rationale behind centralization.
The results supported the importance of learning an organization's history prior to implementing a change, as
well as the need for group development prior to the implementation of a new model within an organization.
The organizational diagnosis I conducted was able to confirm three of four of the hypotheses. I was able to
uncover two variables that I did not consider before the diagnosis: role definition, and inter-group dynamics.
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ABSTRACT 
 
This capstone examines the root cause of the ineffectiveness of a centralized 
Investigational New Drug (IND) core within a research department of a large Academic 
Health Center (AHC). This capstone utilized an organizational diagnosis approach to 
collect data to determine what is and is not contributing to the success of the core.  
The hypotheses of this study are: 1) The centralized model was set in place 
without clear objectives; 2) The IND core is not operating in the way it was structured to 
operate; 3) The IND core is understaffed and unable to fully carry out the level of 
responsibility associated with being a Sponsor; and 4) Future expansion was not included 
in the planning phase.  Data was collected by interviewing staff members, and participant 
observations.  Prior to conducting the current state interviews, I conducted background 
interviews with previous staff members to determine the rationale behind centralization.  
The results supported the importance of learning an organization's history prior to 
implementing a change, as well as the need for group development prior to the 
implementation of a new model within an organization. The organizational diagnosis I 
conducted was able to confirm three of four of the hypotheses.  I was able to uncover two 
variables that I did not consider before the diagnosis: role definition, and inter-group 
dynamics. 
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CHAPTER 1 
 
INTRODUCTION 
 
Clinical research overview   
  I have spent the past ten years working in the field of clinical research, growing 
(or expanding) my working knowledge and understanding of Good Clinical Practices 
(GCP) and regulatory requirements. Until recently, I have never explored the dynamics at 
play within this field, nor have I been able to locate much research on these dynamics. 
This is one reason that this capstone research had particular appeal to me as it allowed me 
to use my knowledge of research regulations and organizational dynamics to diagnose 
one of the current systems in my workplace.  
 This capstone will evaluate the effectiveness of a centralized IND core at an 
Academic Health Center (AHC). My interest in this topic began two years ago when I 
was asked to oversee the operations of the IND core. Since then I have struggled with 
providing the most effective processes for this core. My goal with this capstone is to 
determine if a centralized model is the most efficient and effective way of managing 
multiple INDs within the department.  
History of clinical research regulations 
 Over the past one hundred years, significant events within the field of clinical 
research have led to the development and implementation of regulations. This section will 
present an overview of significant events that led to the development of guidelines 
centered on Protection of Human Subjects and Investigational New Drugs applications.  
The purpose of presenting this literature is to provide the reader with an understanding of 
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the crucial events leading to regulations and processes within the field of clinical 
research.  These events led to (and continue to) regulations concerning protection of 
human subjects and drug-related research.  
 The first event of significance for this capstone is the passing of the Pure Food 
and Drug Act in 1906.  This law mandated all new drugs be tested for safety before 
marketing. The test results were required to be submitted to the Food and Drug 
Administration (FDA) as a New Drug Application (NDA). Unfortunately, this law did not 
prevent tragic events from occurring. In 1937, a drug company manufactured a strep 
throat treatment drug. The solvent included in this drug was poisonous, killing nearly one 
hundred people.  It was discovered that the drug had not been tested in animals or 
humans before being marketed. This event became known as the Elixir Sulfanilamide 
tragedy (White-Junod, 2012). The Elixir Sulfanilamide tragedy led to the passing of the 
Food, Drug and Cosmetic Act of 1938. This law required peer-market review of safety in 
an NDA, and labeling requirements. In addition, this law provided the FDA with the 
ability to audit manufacturing organizations (White-Junod, 2012). “A new provision in 
the act -- requiring drug sponsors to submit safety data to FDA officials for evaluation 
prior to marketing -- appeared with relatively little discussion following on the heels of 
the Elixir Sulfanilamide disaster” (White-Junod, 2012). This statement stood out to me 
because the article did not specify who was involved in the decision-making process. 
This raised some questions in my mind. Was there a thought out plan in place? Or was 
the act instituted as a knee jerk reaction?  The government was liable because numerous 
deaths occurred and in order to demonstrate the problem was being fixed, a regulation 
was developed. 
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 The Nuremberg Code is a regulation that was written in 1948 in response to the 
rights and welfare of human subject research participants and their mistreatment by Nazi 
Germany (Gordon & Prentice, 2000, p.1). “The origin of modern concern for the rights 
and welfare of human subjects participating in research is generally acknowledged to 
have occurred in December, 1946.” (Gordon & Prentice, 2000, p.1)  Twenty-three 
individuals (physicians and administrators) were charged with murder and torture of 
humans for medical science. Between 1942 and 1945, thirty-two experiments were 
conducted on concentration camp prisoners. This code (see the HHS.gov website, 
http://www.hhs.gov/ohrp/archive/nurcode.html) consists of ten standards that must be 
met when conducting human subject related research (Table 1). 
 
Table 1. Nuremberg Code  
Code 
number 
Code  
1 The voluntary consent of the human subject is absolutely essential.  
2 The experiment should be such as to yield fruitful results for the good of society, 
unprocurable by other methods or means of study, and not random and unnecessary in 
nature.  
3 The experiment should be so designed and based on the results of animal experimentation 
and knowledge of the natural history of the disease.  
4 The experiment should be so conducted as to avoid all unnecessary physical and mental 
suffering and injury. 
5 No experiment should be conducted where there is an a priori reason to believe that death or 
disabling injury will occur. 
6 The degree of risk to be taken should never exceed that determined by the humanitarian 
importance of the problem to be solved by the experiment. 
7 Proper preparations should be made and adequate facilities provided to protect the 
experimental subject against even remote possibilities of injury, disability, or death.  
8 The experiment should be conducted only by scientifically qualified persons.  
9 During the course of the experiment the human subject should be at liberty to bring the 
4 
 
 
experiment to an end.  
10 During the course of the experiment the scientist in charge must be prepared to terminate 
the experiment at any stage, if he has probable cause to believe, in the exercise of the good 
faith, superior skill and careful judgment required of him that a continuation of the 
experiment is likely to result in injury, disability, or death to the experimental subject.  
 
 Following the implementation of the Nuremberg Code came strong regulations 
specific to the drug industry. “In 1961, a popular drug in Europe, a hypnotic known as 
thalidomide, was discovered to cause severe birth defects and even death in babies when 
their mothers took the drug early in their pregnancies.  Because of the concerns of FDA 
drug reviewer Dr. Frances Kelsey, the drug was never approved for sale in the U.S.  
Nonetheless, the drug sponsor had sent samples of the drug to thousands of U.S. doctors 
who gave the samples to their patients without telling them that the drug was an 
experimental one, making their patients the unwitting subjects of human drug 
experimentation” (White-Junod, 2012).  This event led to the Kefauver-Harris 
amendments of 1962, which mandated all drugs must be proven safe and effective before 
marketing.  This was the underlying foundation for INDs. 
 In 1964, the World Medical Association (WMA) published the Declaration of 
Helsinki. This document describes ethical principles of conducting research involving 
humans. Gordon and Prentice (2000) state the document breaks medical research into two 
categories: clinical research combined with professional care, and non-therapeutic 
clinical research. This document was built upon the Nuremberg Codes as many American 
Physicians raised concerns about learning from “barbaric” events (Gordon & Prentice, 
2000).  
 The Tuskegee Syphilis Study was conducted between 1932 and 1972. This is a 
widely publicized study, which led to further regulations within the field of clinical 
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research. In the mid-1920s, a health initiative was started within the black community for 
which the Rosenwald fund provided monetary support to investigate treatment options 
for the disease of syphilis.  The standard treatments were salvarsan, mercurial and 
bismuth, which in turn showed minor advantages and high toxicity.  The fall of the stock 
market and Great Depression caused the Rosenwald fund to cut support.  
 In 1932, the United States Public Health Service (PHS) sponsored a study at the 
Tuskegee Institute (and its affiliated hospitals) in southern Alabama. The goal was to 
investigate the stages of syphilis over the course of its lifetime. Two hundred and one 
healthy black males (controls) and three hundred and ninety-nine syphilitic black males 
were enrolled into the study. For the most part, these men were of low income and did not 
know the severity of the disease from which they suffered. At the time of enrollment, they 
were informed they were being treated for bad blood, and in actuality the doctor had no 
intention of treating the disease at all, due to the lack of “safe” treatment options (Center 
for Disease Control and Prevention).  
 The details of this study were revealed in 1972 leading to the National Research 
Act. Simultaneously the Department of Health, Education, and Welfare (DHEW) 
published regulations for the use of human subjects (Gordon and Prentice, 2000). These 
regulations -- known as 45 CFR 46 (Regulations for the Protection of Human Research 
Subjects) -- included the mandate of an Institutional Review Board (IRB) to oversee, 
review studies for safety and established criteria for Informed Consent.  
 These events led the United States to develop regulations for the conduct of 
clinical research. “It should be recognized that the system for protection of the rights of 
human subjects of research, which evolved painfully from the horrors of Nazi Germany, 
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itself continues to evolve” (Gordon and Prentice, 2000, p.7). Clinical research is 
continuing to evolve, and the regulations will need to evolve as well.  
Background 
 The field of clinical research has been evolving over the past century and has led 
to the development of regulations and infrastructure to support the research. Clinical 
research (human subject research/clinical investigation) is defined as “any experiment 
that involves a test article and one or more human subjects, and that either must meet the 
requirements for prior submission to the Food and Drug Administration under section 
505(i) or 520(g) of the act, or need not meet the requirements for prior submission to the 
Food and Drug Administration under these sections of the act, but the results of which are 
intended to be later submitted to, or held for inspection by, the Food and Drug 
Administration as part of an application for a research or marketing permit. The term 
does not include experiments that must meet the provisions of part 58, regarding 
nonclinical laboratory studies (21 CFR 56.102).”  This definition is taken directly from 
the Code of Federal Regulations (CFR).  
 AHCs have a vested interest in the conduct of clinical research protocols. Some 
protocols involve the use of investigational drug therapies, which in turn require the 
submission of an IND application to the FDA, an agency of the US Department of Health 
and Human Services. The FDA is responsible for overseeing the safety of all FDA 
regulated products and overseeing the protection of human research participants for 
clinical investigations.  There are numerous centers under its structure with two specific 
to INDs: The Center for Drug Evaluation and Research (CDER) and Center for Biologics 
Evaluation and Research. A process for submitting an IND is clearly defined in 21 CFR 
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312 and is mapped out in the flowchart below (see Figure 1). The process for submitting 
an IND involves numerous working parts and a high level of expertise for the personnel 
involved.  
 
Figure 1. IND application process  
 
 
Figure 1. Holbein, M. E. Blair, 2009 
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The process of conducting clinical research involves several stakeholders.  Two of 
the primary stakeholders are the Investigator, an individual responsible for the conduct of 
the clinical research (see Table 1) and Sponsor (see Table 2). The standards for 
Investigators are very high, and Investigators are expected to undergo proper training 
before conducting a clinical research protocol (Berro, Marlene, Burnett, Bruce, Fromell, 
Gregg, Hartman, Karen, Rubinstein, Eric, Schuff, Kathryn, & Speicher, L. (2011). 
 
Table 2. Responsibilities of investigators under an IND (21 CFR 312) Regulations 
(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.60)  
Ensuring that an investigation is conducted according to the signed investigator 
statement, the investigational plan, and applicable regulations; for protecting the rights, 
safety, and welfare of subjects under the investigator's care; and for the control of drugs 
under investigation 
Obtain the informed consent of each human subject to whom the drug is administered 
Record keeping and record retention  
Assurance of IRB review  
Reporting: progress, safety and final report 
 
 Investigators wishing to conduct research utilizing an investigation drug must 
meet regulatory requirements above those mandated for Investigators of non-drug related 
research. These additional regulations are set in place to ensure protection of the research 
participants participating in research studies involving the use of a non-FDA approved 
drug. “Individual investigators who initiate and conduct a clinical study, as well as being 
directly accountable for the administration or dispensing of the investigational drug, are 
designated as Sponsor-Investigator.” (Holbein, 2009, p.691) 
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 A sponsor is defined as a person who takes responsibility for and initiates a 
clinical investigation. The sponsor may be an individual or pharmaceutical company, 
governmental agency, academic institution, private organization, or other organization. 
The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-
investigator. A person other than an individual that uses one or more of its own 
employees to conduct an investigation that it has initiated is a sponsor (see Table 2).  
 
Table 3. Responsibilities of a sponsor under an IND (21 CFR 312) Regulations 
(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.50 ) 
Selecting qualified investigators, training  
Providing them with the information they need to conduct an investigation properly 
Ensuring proper monitoring of the investigation(s) 
Ensuring that the investigation(s) is conducted in accordance with the general 
investigational plan and protocols contained in the IND 
Maintaining an effective IND with respect to the investigations, and ensuring that FDA and 
all participating investigators are promptly informed of significant new adverse effects or 
risks with respect to the drug 
Supplying, handling and disposition of investigational products 
Record keeping and record retention  
Management of investigator non-compliance  
Assurance of IRB review  
Medical expertise, trial oversight 
 
Overview of a department within an AHC 
 The department (which has been named Department A to protect its identity) had 
several Sponsor-Investigators prior to the year 2007. Several Investigators within the 
department had an interest in studying the safety and effectiveness of Radio-
pharmaceuticals. A Radio-pharmaceutical is defined as a drug (compound or material) 
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that may be labeled or tagged with a radioisotope.  These Investigators (prior to 2007) 
developed clinical research protocols, and submitted INDs to the FDA.  
 Research being conducted at an AHC entered the spotlight on September 17, 1999 
due to the death of a research participant.  Research restrictions and higher level 
oversight were implemented as a result of the event. The AHC created a centralized office 
– the office of Human Research (OHR) – to provide support to Investigators throughout 
the AHC.  In addition, the AHC in collaboration with OHR reviewed all of the research 
being conducted and determined studies that were considered of greater than minimal 
risk, and needed additional oversight. Department A was considered one of the key 
departments with multiple high risk protocols. In order to ensure compliance, OHR 
developed a monitoring program, implemented in the fall of 2005, for protocols with 
greater than minimal risk. 
 OHR monitored protocols under an IND throughout the spring of 2006. The 
monitoring reports documented non-compliance. The Administrative leadership of OHR 
and SOM met with the leadership within Department A to discuss the findings and an 
action plan. Leadership of Department A was charged with designing a plan to dissolve 
non-compliance among Sponsor-Investigators. The departmental leadership took the 
findings very seriously and decided the department would be named as Sponsor.  
 Simultaneously while these discussions were occurring, leadership was in search 
of a new chief for a division within the department. The selected candidate brought with 
him previous experience of working within a centralized IND core model. He offered his 
expertise of Sponsor requirements and to serve as the Sponsor's authorized-representative 
if hired into the chief position. Soon thereafter, this gentleman was chosen as the 
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Sponsor's authorized-representative on behalf of the Sponsor.  
 
My involvement 
 I began working in the department in the fall of 2002 as a Clinical Research 
Coordinator (CRC) for Dr. X on a multi-modality project that lasted until June 2007. 
During the five-year period, I gained extensive knowledge of clinical research conduct 
and advanced into a project manager position. Shortly after the completion of the project, 
Dr. X promoted me to a senior level project manager and requested I work with him to 
develop a centralized Clinical Research Coordinator core (known as RADCORE). I 
created training manuals, protocol file templates, regulatory organization tools, standard 
operating procedures, and hired several new CRCs into the group. I was proud of my 
accomplishments and found the core was operating smoothly. I was eager to take on more 
responsibilities within the department.  
 My involvement in the IND core began two years ago; I was a young, enthusiastic 
worker willing to take on extra responsibilities and sought out challenges. My role 
evolved early in 2010; I was promoted to Clinical Research Operations Manager. My 
responsibilities included developing operational processes, managing projects, and 
leading research staff throughout multiple cores of the research unit of the department.  
 Late January 2010, I received an email from my boss, Dr. X, requesting I help 
organize and improve the document management quality of the IND core.  I had little 
knowledge of the current organizational structure within the IND core and was not aware 
of the history of the OHR audits so, I was a bit nervous about this new responsibility.  
 When I spoke with Dr. X he explained he needed my help organizing the 
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regulatory files of the IND core, creating a more effective and efficient organization 
system, and hiring an individual to serve as the IND Manager.  He briefly explained the 
IND core had been centralized for three years (implemented in 2007) and was still not 
operating effectively. The centralized model was set in place because individual 
investigators did not have the resources to maintain compliance with the regulations. To 
solve this problem, the department was named Sponsor and an individual was appointed 
as Sponsor's authorized-representative.  In addition, an IND core manager was hired to 
manage the administrative activities and monitor research protocols under INDs.  
 Since the IND core was a newly adapted model and not one that other department 
were utilizing, the AHC leadership were watching carefully. OHR has been conducting 
audits of the IND core throughout the 2009 academic year, and the audit findings 
included:  lack of communication with Investigators, missing documentation, lack of 
training, and lack of documented communication among all working parts of the core.  
OHR provided recommendations for re-organizing and resolving the major audit 
findings. Unfortunately, the findings were not resolved and the core was at risk of being 
closed down. Dr. X explained a change in administrative staff was warranted, and a new 
individual would be hired under my supervision. Before I could go through the 
recruitment and hiring process, my first priority was resolving the auditing findings.  
 I spent the next several months going through regulatory files, creating tracking 
systems, and resolving most of the findings from the 2009 OHR audits. I remember 
feeling fairly confident in the systems I had created and felt strongly it was time to focus 
on recruiting and hiring an IND core manager. I met with Dr. X and Dr. Y (Sponsor-
Representative at the time) to determine the responsibilities that would be associated with 
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the position. After a few discussions with both leaders and researching IND Manager Job 
descriptions, I drafted the position summary and submitted it to Human Resources for 
approval and posting.  
 I interviewed several candidates who demonstrated knowledge of clinical 
research, FDA regulations, Good Clinical Practices, communication, organization, and 
initiative competencies.  With buy-in from Dr. X, and Dr. Y, I made a decision on the best 
suited candidate for the IND Manager position. I offered the position to an internal 
candidate in the department, who demonstrated all of the above mentioned qualities. She 
accepted the offer and started her new position in June 2010. 
 My goals (agreed upon by IND Manager ) for the IND core included: developing 
a monitoring plan, Sponsor Standard Operating Procedures (SOPs), training manual for 
Investigators, a website, standard filing naming conversions, electronic file management, 
and standard file organization. In addition to all of this, I knew the daily operations had to 
continue. The IND Manager took the lead on filing annual reports (for each IND) 
protocol amendments and new protocols to the FDA. She continued maintaining the site 
files of protocols under each IND and defining regulatory submission processes for 
Investigators, a monitoring plan, and wrote out the mission of the IND core. These three 
tasks were quite a challenge because we did not know if our perception of the core 
matched the unspoken mission Dr. X and Dr. Y had intended.   
Problem statement  
 The centralized IND core was developed and implemented to resolve non-
compliance issues among Sponsor-Investigators; however, non-compliance issues were 
still noted on audit reports after the implementation of the centralized IND core.  The 
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centralized model was not fully implemented, nor fully staffed to operate in the way it 
was structured.   
 There are several assumptions I have which led me to conduct this diagnosis. 
These assumptions include: There was a lack of planning about the infrastructure for the 
centralized IND core, roles were not identified and the purpose of the core was not 
clearly defined.   
 Over the past two years I have been concerned with the lack of Sponsor 
responsibilities remaining unmet by the centralized core. The three responsibilities not 
being fulfilled by the centralized core include: monitoring, drug accountability, and 
training. In addition to my observations, the lack of fulfillment has been documented on 
routine audits by OHR. I feel these issues are present because leadership did not clearly 
define the core's infrastructure prior to implementation.  
 The second assumption I have is,   operating effectively because roles were not 
clearly identified at the time of implementation. When I was first asked to assist with the 
core, I was introduced to two people: the core manager and the sponsor-representative. 
The other indirect members (regulatory and cyclotron) were not discussed. At the time, I 
assumed the only two individuals that mattered to the operation of the core were the 
manager and the sponsor-representative.  Presently, the core manager and I meet monthly 
with the -representative to discuss the operations of the core. Recently, I have noticed the 
other indirect members are important to the operations.  I’m concerned that the absence 
of these members from monthly meetings is hindering the effectiveness of the core. Each 
of these individuals has important skills that could contribute to the effectiveness of the 
core. The regulatory manager is knowledgeable of FDA regulations and could assist in 
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the development of effective processes and the cyclotron manager has the most 
knowledge of drug production.  At this point, it is not clear how involved these 
individuals should be in the core.  
 The goals of the core have not been made clear. Initially, I had a very limited 
understanding of the IND core and the purpose it served within the department.  I also 
had a very limited understanding of the role of sponsors. I read section 312 of the CFR to 
better acquaint myself with the regulations centered around INDs.  Sponsors have 
specific responsibilities and per FDA regulations must be met. I do not believe leadership 
clearly identified if the centralized core was going to handle the full responsibilities of a 
Sponsor.  
 My goals with this capstone are to learn more about the rationale of developing a 
centralized core, and understand the reason the IND core is not fully functioning as a full 
service centralized IND core.  In order to fully understand the problem, I will conduct a 
diagnosis of the organization described above.  
 In Chapter 2, I review literature pertaining to conducting an organizational 
diagnosis, the importance of understanding an organization's history, and the historical 
events leading to clinical research regulations.  In Chapter 3, I outline the methods I used 
to explore my hypotheses. I will explain why I selected structured interview questions, as 
well as how I plan to carry out the diagnosis.  In Chapter 4, I present the data and my 
interpretation of the data. I will then provide a detailed summary of feedback for the 
client system. I conclude this thesis in Chapter 5 with a summary of my findings and 
learning from performing the diagnosis.  
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CHAPTER 2 
 
LITERATURE REVIEW  
 
Introduction 
 
 In this literature review I will discuss three areas of research: organizational 
diagnosis, organizational history, and the history of clinical research regulations.  I will 
begin by describing the important elements involved in conducting an organizational 
diagnosis. I review this literature in order to demonstrate the ways in which an 
organizational diagnosis can contribute to our understanding of why an organization is 
not functioning effectively. The second area of research which I discuss is organizational 
history. I reviewed literature centered on the importance of understanding an 
organization's past and the impact it has on the present and future. The final section of 
this chapter presents literature evaluating support programs at AHCs.    
Organizational diagnosis 
 
 The focus of this capstone is the diagnosis of a centralized IND core within an 
AHC.  It is critical for me to explain the importance and relevance of conducting an 
organizational diagnosis because the framework of my capstone is a diagnosis of my 
current workplace.  After searching through literature extensively, I was unable to find 
literature specific to diagnoses of academic health centers. The lack of literature 
highlights the importance of this capstone, as it begins to fill the gap within the literature.  
I will present the importance of conducting a diagnosis within an organization.  
 Clayton P. Alderfer describes the methods of organizational diagnosis in his article 
“The Methodology of Organizational Diagnosis” (Alderfer, 1980)  as a process of 
entering a human system, collecting data, and feeding that information back to the system 
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to increase understanding among the system's members. Based upon what is learned, a 
determination regarding change can be made.  While this may seem like a lengthy task, 
the performance of an organizational diagnosis is a stepping stone to a successful and 
productive change management program (if applicable).  
 "The purpose of organizational diagnosis is to establish a widely shared 
understanding of a system and, based on that understanding to determine whether change 
is desirable” (Alderfer, 1980, p.459). Conducting an organizational diagnosis is important 
for several reasons. The first is a diagnosis can provide data valuable for testing a 
hypothesis, rather than speculating about the cause of the problem. The second reason for 
conducting an organizational diagnosis is to focus on determining the root cause of a 
problem, rather than focusing on the symptoms of the problem. The third reason for 
conducting a diagnosis is to identify factors that may be causing the problem, but are not 
visible. These three points emphasize the importance of understanding the overt and 
covert dynamics of an organization.  
 Managers are charged with getting an organization to operate effectively. This can 
be an overwhelming and challenging task, to say the least. “Understanding one 
individual's behavior is challenging in and of itself; understanding a group that's made up 
of different individuals and comprehending the many relationships among those 
individuals is even more complex” (Nadler & Tushman, 1980, p.35).  There is a pressing 
need for a manager to manage organizational behavior. Nadler and Tushman (1980) state 
the manager can learn to predict and control organizational behavior with tools to fully 
understand the dynamics at play. One tool is a model. “A model is a theory that indicates 
which factors are most critical or important” (Nadler & Tushman, 1980, p. 36).  There are 
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several different models that can be used when conducting an organizational diagnosis.  
Utilizing an organizational model can help diagnosticians understand the problem 
systemically.  
 Nadler and Tushman (1980) describe the diagnostic model as a model that 
describes the system, identifies the problem, and also analyzes the fits.   This model is 
known as the congruence model.  “The model also implies that different configurations of 
the key components can be used to gain outputs. Therefore, the question is not how to 
find the "one best way" of managing, but how to find effective combinations of 
components that will lead to congruent fits among them.” (Nadler & Tushman, 1980, p. 
46).  
 Marvin Weisbord (1976) developed the “six box model” as another model for 
diagnosing organizations. This model consists of six components: purpose, structure, 
relationships, rewards, leadership and helpful mechanisms. Weisbord (1976) explained 
the purpose of this model as a model allowing consultants to apply theories they know 
and to discover new connections.   
 Weisbord (1976) noted, “There are two main reasons why one might want to 
diagnose an organization: to find out systemically what its strengths and weaknesses are 
or to uncover reasons why either the producers or consumers of a particular output are 
dissatisfied” (p. 435).  
Determining the underlying root cause is another reason why conducting an 
organizational diagnosis is important. There is often confusion between symptoms and 
root causes. A root cause is the underlying problem often masked by symptoms. Freeman 
and Zackrison (2001) describe symptoms and root causes with a medical metaphor. 
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Individuals will experience a high fever as a symptom to an underlying medical 
condition. In order to fully cure the fever, a medical professional must identify the 
underlying cause. However, this level of diagnosis may not always occur. As argued by 
Freedman and Zackrison (2001), “Many people settle for immediate, temporary relief 
they get by treating their symptoms; If they can endure it and it goes away, they've saved 
time and money” (p.27). One can argue that the temporary relief of symptoms is not 
diagnosing or treating the underlying problem. In turn, this could potentially cause more 
harm in the future.  
 The above metaphor illustrates the importance of finding and treating the root 
cause. The same can be applied to diagnosing an organization. Consultants and leaders, 
who choose to find and treat the underlying cause, can begin the diagnosis process with 
asking open-ended questions. The purpose of doing this is to gain perceptive from as 
many avenues as possible.  
Alderfer (1980) describes three phases of a diagnosis: entry, data collection and 
feedback. I want to briefly describe the entry and data collection phases as they were 
specific to my experience with this capstone.  Entry is the first phase of a diagnosis. 
Alderfer (1980) theorizes that internal (to the system) people cannot act as consultants to 
the system.  
All individuals have vested interests in their own organization. Even if 
individuals did not press their own interest, other members of the system 
would be unable to accept a consultant relationship from a peer, and the 
complete insider would be rendered ineffective as a result (p.461) 
 
I did not experience a definite point of entry with this capstone. I've been a staff 
member of my organization for ten years and am familiar and comfortable with the 
operations of the organization. I found my experience to be the opposite.  I observed the 
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participants as accepting and supportive of the diagnosis. Due to my personal experience 
and journey, to an extent, I disagree with Alderfer's perspective on internal consulting. 
Internal consulting can be essential for the growth and change of an organization. Internal 
consultants possess knowledge of background information, the system, and established 
relationships with people that are a benefit to conducting a diagnosis. Although, I must 
ask the question, will leadership accept my findings? Or would these be better received 
from an external consultant?  
 There are differences between external and internal consulting. For this literature 
review, I will focus specifically on internal consulting. Miriam Lacey (1976) describes 
the role of an internal consultant as being unique. These are usually individuals hired to 
serve as an organizational development professional for a specific organization.   I also 
believe these professionals could be line managers/general managers interested in 
learning change management techniques to apply within their organization.  My 
relationships with staff members, accessibility to schedules, and personal role within the 
organization contributed to the ease I experienced with understanding the background of 
the issues present within the organization.  
 Interviewing is a method of data collection. This is an opportunity to speak with 
staff members individually or as a group. “Individual interviews have a relationship-
building quality if they are conducted competently and, as a result, are probably the most 
essential tool of any data collection” (Alderfer, 1980, p. 463). The data provided from 
individual staff interviews is rich. This point of the diagnosis provides the consultant with 
individual perspectives, archival documents, and a chance to observe reactions.  
 The diagnosis process is a way to determine the cause of the problem without 
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focusing on the symptoms. “The aim of an organizational diagnosis is to produce learning 
about the system for its members” (Alderfer, 1976, p.369). Taking time to really 
understand what is going on within an organization will produce a common 
understanding and ability to produce change if applicable.  
Underbounded systems 
As a consultant, it is important to understand the type of system you are entering so 
you can really navigate through the system and understand the contributing factors to the 
issues. Specifically for this literature review, I will focus on underbounded systems and 
how they are perceived. Alderfer (1980) theorizes two system types: overbounded and 
underbounded. But, the bigger question is, what is a system?   
A system is a set of units with interdependent relationships among them     
(p.269).  
 
The systems are designed with boundaries, allowing exchanges to occur internally 
and externally. Alderfer identified three system categories: optimal, overbounded, and 
underbounded. The optimal system allows for just the right amount of permeability 
between the system and the outside. Overbounded and underbounded are the opposite 
extremes of optimal. Overbounded systems do not allow for much permeability, and 
underbounded systems allow for too much permeability (Alderfer, 1980).  Is a system 
always bound to be one type versus the other? Based on Alderfer’s definition of a system, 
I would argue the system type can be altered when there are changes to the units within. 
This could include the addition of a unit.  How can one distinguish between the systems 
they are consulting to?  Alderfer identified eleven interdependent variables that 
distinguish the difference between the two system types (see Table 4). 
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Table. 4. Alderfer’s (1980) system type variables 
1. Goals 
2. Authority relations 
3. Economic conditions 
4. Role definitions 
5. Communication patterns  
6. Human energy 
7. Affect distribution  
8. Intergroup dynamics 
9. Unconscious basic assumptions  
10. Time-span 
11. Cognitive work 
 
 
The four variables that stood out most for this capstone included: goals, authority 
relations, role definitions and intergroup dynamics. I will focus specifically on these four 
variables and how these relate to the organizational diagnosis I conducted.  
Goals are highlighted as things that partly define an organization (Alderfer, 1980).  
The lack of goals can cause confusion and uncertainty among individuals and groups in 
the system.  The confusion can be twofold: either individuals are unclear about the goals, 
or unclear about which goals have priority.  “Increasing the clarity of organizational goals 
or the degree of consensus about goal priority is associated with decreasing boundary 
permeability and decreasing the clarity of organizational goals or increasing the disputes 
about goal priority is associated with increasing boundary permeability" (Alderfer, 1980, 
p.270).  Alderfer provides a detailed description of what to look for as consultants, but the 
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question remains, how can we achieve optimality?   
The second variable to be aware of is authority relations. The boundary type of 
the system can be influential to the leadership style and vice versa (Alderfer, 1980).   
Within an organization the style of leadership impacts the organization as a whole as well 
as the individuals that are part of the organization. In an overbounded system there is 
usually a centralized and hierarchical approach to leadership. In this type of system, there 
is usually an agreement upon the goals, and purpose (Alderfer, 1980).  On the contrary, 
the underbounded system results in unclear goals as well as a fragmented style of 
leadership. There will either be multiple authorities, or none (Alderfer, 1980). In my 
opinion, leadership is the important foundation and support to an organization. As 
consultants, during a diagnosis it is critical to review and understand the relationships 
with authority. Understanding how employees work with their leader can demonstrate the 
level of leadership involvement within the system and the level of comfort employees 
experience.   These understandings will also help build the effectiveness of a feedback 
session. 
The third variable is role definitions. “Individuals in organizations develop 
patterns of role behavior based on the expectations placed upon them by the organization 
modified by their own personal values, beliefs, abilities, and group memberships” 
(Alderfer, 1980, p.272). Often times, individuals will carry out responsibilities that are 
assigned to them as well as taking the initiative to find other responsibilities to complete. 
On the contrary, individuals may alter the responsibilities assigned to them by narrowing 
the focus of said responsibilities and altering the scope of work within their role. The 
style of authority may also impact the roles of group members. Leadership may not be 
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clear or direct about assigning tasks or defining, at the group level, the responsibilities. 
This can often be seen in an underbounded system if the authority is not clearly 
identified.  
The fourth variable related to this capstone is intergroup dynamics. Intergroup 
dynamics is defined as relationships among various groups within the system (Alderfer, 
1980). Alderfer (1980) breaks intergroup dynamics into two classes: 1. Task groups and 
2. Identity groups.  
Task groups are defined by the kinds of work they perform and by the level in the 
hierarchy in which they are located. Identity groups refer to group affiliations that 
help individuals shape their personal identities (example: ethnic, gender, 
generation, and other groups determined by life experiences (274-275).  
 
Alderfer theorizes underbounded systems will usually have intergroup conflicts 
between the identity groups whereas task group conflicts are more prevalent in 
overbounded systems. I would also note that tasks groups in underbounded systems may 
exhibit intergroup conflicts due to the lack of role clarity and leadership.  
 It is critical for a consultant to spend time determining the type of system they are 
entering in order to provide a successful diagnosis. Gaining a sense of understanding of 
the specific variables will give the consultant determination on if the variables can be 
changed to achieve an optimal system.  
Planning 
 I was unable to locate literature specific to planning processes within AHCs. 
Again, I believe the lack of literature highlights the importance of this capstone and 
future research on this specific topic.  Based on historical events, programs and 
regulations have been set in place as a reaction to a tragic event.  I have not been able to 
determine if planning was done prior to implementation. The historical events 
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demonstrate the lack of proactive approaches with enhancing compliance.  
 I reviewed literature that highlighted inaccurate planning in terms of projecting 
costs, demands and resources. This literature is relevant in highlighting how planning can 
be inaccurate, but it is not relevant to the purposes of this capstone.  
History of organizations 
 
While the goal of this capstone is to determine why the IND core is not presently 
operating effectively, it is important to understand the historical events that shaped a 
centralized IND model as the history is a factor in the current state of an organization. For 
this capstone I am focusing on a specific unit within a large organization.  Therefore, I 
will examine the literature on organizational history from this perspective. I will discuss 
the importance of gaining an understanding of the organization's history, and how history 
affects the current state. Following this, I will outline the history behind clinical research 
regulations.  
There are few practitioners that focus on the past when entering a client system. 
“Transformation cannot simply be mandated. To be effective, it must be undertaken in a 
way which builds on rather than runs over the past.” (Kimberly & Bouchikhi, 1995, p.9) 
 Kimberly and Bouchikhi (1995) argue that an organization is somewhat analogous 
to an individual. There is a culture that appears within an organization, which in turn 
produces an identity that is easily noticeable. (Kimberly & Bouchikhi, 1995). When 
attempting to understand behaviors of individuals, practitioners/clinicians ask questions 
about the individuals past in order to fully understand why they behave in a certain way. 
This same approach can be taken with organizations. Consultants can ask questions, and 
research the past to determine why the organization operates in a certain way.  
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We would argue that without an appreciation for past experiences, present 
behavior and future action cannot be fully understood for people or for 
organizations (p.10). 
 
 This argument presents the value of an organizational biography. “Biography is a vehicle 
for illuminating the lives of individual people.” (Kimberly & Bouchikhi, 1995, p.10)  
 Over the past few years, there has been an increase in awareness as to the benefits 
of a biographical approach; however, some still argue over the function of the 
biographical approach to research. “Some argue that they should provide comparable data 
for building generalizable theories, while others argue that they should provide a means 
for underlining uniqueness.” (Kimberly & Bouchikhi, 1995, p.10)  As I conducted my 
research, I found creating a biography of the IND core provided relevant knowledge that 
would benefit the current leadership, as well as providing external leadership and 
understanding of the uniqueness of our unit.  
 But, how can an organization’s historical events be obtained? Simmons describes 
the data available from historical research as that of memories and paper records 
(Simmons, 1985).   Learning about the history of the organization can be gained through 
qualitative data, and a review of past records. Kimberly and Bouchikhi present a study 
demonstrating how history shapes an organization. In-depth interviews with the CEO and 
staff members were conducted over the course of five months. The purpose of conducting 
these interviews was to gather an understanding of the development of the company. 
Kimberly and Bouchikhi noted in their article, “The Dynamics of Organizational 
Development and Change: How the Past Shapes the Present and Constrains the Future”, 
the limitations associated with the qualitative research approach. Individuals may not 
fully remember all of the details associated with the past. However, while there may be 
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limitations, the stories being told by each participant are the stories that shape the 
organization's current state.   Simmons argues there is a need to build models to 
understand distortion and fact (Simmons, 1985). She breaks her models into three 
categories: distortions about involvement, distortions about time, and distortions noted in 
the interviews. With the distortion of time, Simmons demonstrates the importance of self-
data (example: memories) because some things may be left out in the discussions. The 
next aspect of the model indicates that individuals may alter in their mind the length of 
time spent in specific relationships.  The third aspect of the model demonstrates the 
importance of observing body language and expressions during interviews.  Simmons 
was able to cross-examine her interviewees with paper documents to assist in recreating 
the history (Simmons, 1985). Utilizing several methods of data collection can help 
produce a more valid and reliable data set.  
 The authors demonstrate that learning the organization's history will assist in 
understanding the current structure and aid in production of successful and effective 
change within an organization. Kimberly and Bouchikhi state: 
And as biographies accumulate, the potential to do comparative work invariably 
increases, enabling one to examine the extent to which insights developed in one 
setting have wider adaptability and thus dramatically heightening the payoffs from 
this kind of work (p.17).   
 
 Over time, organizations change in terms of structure and culture. An organization 
is shaped by its identity. Can-Seng Ooi (2002) described identity by noting “Albert and 
Whetten defined organizational identity as the central, distinctive and enduring aspects of 
the organization” (p.606), According to Can-Seng Ooi (2002) this type of theory can 
marginalize the complexity of organizational change dynamics and decrease the reality 
(p.606). Ultimately, this may provide individuals with a skewed opinion of an 
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organization based on a limited understanding.  
 How should history be presented to individuals? Ooi describes the following two 
processes for providing a packaged history to individuals.  “The re-presentation of history 
involves interpreting the bygone for a uniformed public, and highlights the emotional 
dimension of communicating history, which has been taken-for-granted and under-
theorized” (Ooi, 2002, p.607).  I believe this statement highlights the importance of 
understanding history as well as learning effective ways to teach the history.  
 History is unique and defined as a narrative account of events. History is about 
facts of the past, but interestingly enough, these are facts that cannot be observed 
presently. Ooi (2002) stated “historical facts, meanings and significance have to be 
packaged for people” (p.607). The history needs to be packaged so that individuals can 
effectively understand what they are being taught without seeing it for themselves.  A 
packaged past mainly consists of details of what happened, why it happened, and the 
significance of the events (Ooi, 2002). What is the motive for presenting a packaged 
history?  
 There are many reasons for presenting a packaged history. Ooi outlined the 
following reasons: traditions, reputation, claims and breaking away from the past.  For 
this paper, I believed it was important to learn the history of the IND core in order to gain 
a deep perspective on the functioning of the core. In addition, I believe presenting these 
findings to current members and future members of the core will provide them with the 
facts of centralization and have an understanding of how to continue to assisting 
Investigators.  
 The dynamics of an organization are complex. “First, tapping into organizational 
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pasts is a complex process and we, as researchers, have to take into account and reflect 
upon our emotional responses to what we have accepted as history” (Ooi, 2002, p. 619).  
When we research history, our perception of what we read or hear may contribute to how 
we feel about the past. It is important that we do not allow inferences to get into the way 
of packaging history.  “Second, we also re-present history, which our packaged pasts 
inevitably draw emotional responses from our audiences” (Ooi, 2002, p.619).  When 
teaching people, we must be aware of the emotion that may be unleashed during the 
presentation.  It is important to be prepared to manage these types of responses.  These 
are important factors to take into consideration before researching organizational history.  
 Reviewing the past will guide individuals (organizations) to understand the 
behavior of the organization and learning about how to develop the future. Often times 
professionals wonder “why do we have to follow this process?”  We may need to dig 
deep, but there is a reason the process was developed. Understanding the history of 
“why” will help organizations and managers build the knowledge base needed to define 
the reason a process is in place.  I believe the history and past is really important as it 
paints the picture of what the organization has become today.  
Clinical research regulations 
 As outlined in chapter one, there have been multiple events leading to the 
development of clinical research regulations over time.  There is limited research on the 
effectiveness of the regulations developed as a result of tragic events. However, there 
have been articles published on the evaluation of IND support programs at AHCs.  
 “Complying with the FDA's regulations can be daunting and an overwhelming 
burden to faculty research who are rarely familiar with their obligations as sponsors of an 
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IND or IDE application” (Arbit & Paller, 2006, p.146). The University of Minnesota 
established an IND/IDE Assistance Program (IAP) in 2002 to assist Investigators with the 
IND/IDE process. The objectives of the program were two-fold: training/education for 
the research team about the regulatory progress and ongoing support to assure Sponsor-
Investigator responsibilities are being met.  Many people may wonder why such a 
program would be established at an AHC where research is high on the priority list.  
 The University of Minnesota established the program as a result of leadership 
concerns about the familiarly Investigators had about research regulations. “Unfamiliarity 
with the required regulations places the researcher and the university at risk of non-
compliance. Research participants’ safety is of course, the primary concern. Attempting 
to learn the regulations and how to apply them took valuable time away from conducting 
the clinical trials” (Arbit &Paller, 2006, p. 148). Arbit and Paller did not provide further 
explanation as to why learning research regulations stood in the way of conducting the 
clinical trials.   I think it would have been interesting to learn about the training 
physicians underwent prior to becoming Investigators.  Perhaps, providing a more 
comprehensive training program for Investigators may have been an option.  
The University of Minnesota documented the successes and failures of 
establishing the IAP. The program successfully established a system to guide 
Investigators in determining if an IND/IDE is applicable for their research. This is often a 
tedious task for Investigators and the additional level of support demonstrated a helpful 
tool for Investigators.  In cases where an IND/IDE is required, Investigators often feel 
bogged down by the process. The establishment of the IAP proved to be a quick process 
for the establishment of research protocols. Arbit and Paller (2006) reported: 
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One researcher delayed progress on a study of a new surgical device for more 
than 12 months because he had no idea where to begin or where to turn. Within a week of 
contacting the IAP, a draft of the IDE application was completed and within a month, the 
IDE application was submitted (p. 152).  
 
These two services provided investigators with support from experienced 
regulatory personnel, who contribute full time efforts to understanding FDA regulations. 
Other report successes with the establishment of the IAP include: development of case 
report forms, monitoring plans, and drug accountability logs, working with external drug 
vendors, Coordinator training, and assisting Sponsor-Investigators with reporting.  
Along with the successes, there was some learning. The biggest challenge faced 
by the staff of the IAP was resistance from some Investigators, who managed and 
submitted their own INDs/IDEs successfully.  “These individuals were reluctant to 
change and to accept regulatory assistance and guidance” (Arbit and Paller, 2006, p.152).  
To my knowledge (Arbit & Paller, 2006), when a new program is established without 
buy-in from all stakeholders, resistance is met. This was a key lesson learned from the 
University of Minnesota. On several occasions the FDA refused to provide information to 
the IAP regarding an IND because the IAP director was not the IND Sponsor. In turn, the 
IND Sponsor wrote a letter granting permission for the FDA to communicate to the IAP 
director.  
Overall, the IAP program provided much needed support to the Sponsor-
Investigators across the University of Michigan.  The article did not specify if the 
successes and lessons learned were noted by the IAP staff or Investigators. The program 
was set-up to be a support for Sponsor-Investigators rather than take on the full 
responsibilities of a Sponsor. Is this the best type of office? Or would it be of more 
benefit to have a centralized Sponsor?  
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“In 2004, the National Institute of Health (NIH) launched the “NIH Roadmap for 
Medical Research” to address roadblocks to research and to transform the way 
biomedical research is conducted by overcoming specific hurdles or filling defined 
knowledge gaps” (Berro et al, 2011, p.2). One of the objectives of this program was to 
enhance translational research. The IND/IDE task force was put together to evaluate the 
support for Sponsor-Investigators. In 2008, the task force developed a pilot study to 
evaluate the current system for Sponsor-Investigator support at AHCs.  The study 
consisted of surveying twenty-four AHCs that provide regulatory support. The survey 
was administered to the regulatory representative at each AHC. The questions were 
developed to assess the level of support offered at each AHC.  
The results demonstrated a wide range of regulatory support provided at each 
AHC. The various models used to support AHCs include: Independent, Consultation and 
Full service (see Figure 2).  These results evaluate three different types of support models 
within AHCs.  As you noted in the figure below, there are positives and negatives to each 
model. Department A appears to be a full service model type. I wanted to highlight the 
research evaluating these various models to highlight the importance of being aware of 
the positives and negatives associated with each. “ The NIH Roadmap for Medical 
Research and the CTSA initiative have contributed to increased recognition of the 
complexities introduced by innovative clinical research conducted at AHCs” (Berro et al, 
2011, p. 6). Overall, the survey reinforced the need for regulatory support programs at 
AHCs. The programs will continue to provide a level of relief that professionals with 
solid regulatory experience are overseeing the conduct of clinical research. 
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Figure 2. Institutional support of Sponsor-Investigators 
 
Again, there is a gap of literature evaluating the successes and failures of 
implementing regulations and rules within the field of clinical research.  The purpose of 
presenting the above literature was to validate the need for some level of regulatory 
support within an AHC.  In addition, the gap within the literature validates the importance 
of this capstone.  
The literature for this capstone is very sparse; however, the lack of literature 
Illustration 1: Figure 2: Berro et. al, 2011, p.6 
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highlights the need for future research to be conducted within the field of clinical 
research. The literature I did present within this chapter highlights the importance of 
learning the history of an organization,  understanding underbounded systems, planning 
and review of clinical research support programs. 
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CHAPTER 3 
 
METHODOLOGY  
 
 The centralized IND core was developed and implemented to resolve non-
compliance issues among Sponsor-Investigators; however, non-compliance issues were 
still noted on audit reports after the implementation of the centralized IND core.  There 
are several assumptions I have developed over the past two years leading to my interest 
in exploring the hypotheses outlined below. 
  The first assumption is, due to a lack of planning, the core is not fulfilling all 
Sponsor obligations.  Over the past two years I have been concerned with the lack of 
Sponsor responsibilities remaining unmet by the centralized core. In addition to my 
observations, the lack of fulfillment has been documented as major findings by the 
research services office. The three responsibilities not being fulfilled by the centralized 
core include: monitoring, drug accountability, and training.  
 The first responsibility not being met is monitoring of research protocols.  I have 
met with the IND core manager on several occasions to discuss monitoring. The core 
manager expressed her concerns with being over-worked with other obligations. She did 
not feel she could dedicate additional time to complete monitoring. We both brought this 
concern to the Sponsor-Representative, who in turn confirmed the importance of the 
tasks, but was comfortable with the lack of monitoring at this time due to the annual 
audits conducted by research services. While I accepted this answer, I am still concerned 
with the lack of monitoring. I began to question the clarity of our role as a centralized 
core. There are multiple responsibilities associated with being a Sponsor. Often times 
when an Investigator takes on this additional role, they are supported by multiple 
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administrative staff members. The centralized model took all associated responsibilities 
away and only hired one full time administrative staff member. These actions left me 
wondering what type of model the core was designed to be. Was the core designed to be a 
full service IND core?  
 The second responsibility not being fully met is documentation of drug 
accountability. There is a lack of documentation between all working parts of the core 
(drug production, handling, and administration). To my knowledge, each sub-group is 
managing their own documentation; however, there is a lack of collective documentation 
of these records. I’m concerned with the lack of collaboration among the key groups of 
the core. Prior to centralization, these sub-groups managed their drug accountability 
separately. I would have assumed a collective area for managing documentation would 
have been put in place with centralization.  I began to wonder if the goal of centralizing 
was to improve document management practices or possibly some other hidden motive.  
 The third responsibility not being met is training.  A Sponsor is responsible for 
training Investigators on regulations and providing oversight. During my first year of 
managing the core, I noticed the Sponsor was not fulfilling the responsibility of training.  
Training Investigators on regulatory requirements of protocols involving radio-
pharmaceuticals is important. The lack of training often has me wondering if these 
Investigators really understand the radio-pharmaceutical they are investigating and their 
obligations as an Investigator.  I have often witnessed an Investigator submit a protocol to 
the IND core, without a fully written protocol, and the essential documentation needed to 
conduct an IND related trial. In these special circumstances, the IND core manager has 
taken time to work directly with the Investigator to ensure they fully understand the 
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requirements of an IND application.  
 The second assumption is, due to role identification, the core is not operating 
effectively. I was asked to step in and help “clean up” the files after issues of non-
compliance were still found on audits. Shortly thereafter, I was appointed an operations 
manager for the core.  My role is to oversee, support, design processes, and supervises 
the core manager.  My involvement with the other members of the core is in-direct.  Over 
the past two years, I have worked closely with the core manager on brainstorming 
monitoring plans, drug accountability tracking, and training programs.  We've developed 
templates, but we have not been able to implement any of them to date. Since, my 
involvement is limited; I haven't felt comfortable trying new plans. Furthermore, I’m not 
clear on the specific responsibilities of the indirect members of the core.  
 The core manager and I meet monthly with the Sponsor's authorized 
representative; however, the regulatory manager and cyclotron manager are absent from 
these meetings. I’m concerned that the absence of these key members is hindering the 
effectiveness of the core. Due to the lack of clarity with the delegation of roles and 
responsibilities, the core is not operating in the way it was structured to operate.  
 At the time the IND core was developed and implemented, the core supported 
four INDs and eight protocols. Over the past five years, the core has grown to manage ten 
INDs, and thirteen protocols. As previously mentioned, I supervise the IND core 
manager. I meet with this individual on a monthly basis to review tasks and to discuss 
issues (if any) that may have arisen within the monthly period. Our discussions are 
mainly centered on the document management process and development of operational 
processes. The core manager is expected to maintain complete files for INDs that were in 
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existence prior to centralization. Attempting to locate historical documentation has been 
challenging and time consuming. These tasks are expected to be completed as well as 
maintaining ongoing documentation and communication.  
 My third assumption is the goals of the core have not been made clear. Initially, I 
had a very limited understanding of the IND core and the purpose it served within the 
department.  I also had a very limited understanding of the role of Sponsors. I educated 
myself by reading section 312 of the CFR (regulations specific to INDs).  Sponsors have 
specific responsibilities and per FDA regulations must be met. I do not believe leadership 
clearly identified if the centralized core was going to handle the full responsibilities of a 
Sponsor. 
 My goals for this capstone are to learn more about the rationale of developing a 
centralized core, and understand why the IND core is not functioning as a full service 
centralized IND core. The hypotheses I will explore are:  
Hypotheses: 
 
• The centralized model was set in place without clear objectives. 
• The IND core is not operating in the way it was structured to operate.  
• The IND core is understaffed and unable to fully carry out the level of 
responsibility associated with being a Sponsor. 
• Future expansion was not included in the planning when the centralized model 
was implemented.  
Investigative methods 
 In order to fully explore these hypotheses, I will conduct two sets of interviews: 
background and current state. The purpose of these interviews is twofold: to determine 
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the key reasons for creating a centralized structure, and to determine if the IND is 
presently functioning effectively. In addition to conducting interviews, I will review audit 
reports, job descriptions, regulatory files, and email communications. I attempted to 
locate a documented vision, and business plan, but was unsuccessful.  
Background interviews 
 
 In order to fully understand the rationale for the development and intended 
structure, I will conduct five in-depth interviews with key stakeholders.  The participants 
chosen for these interviews were key departmental personnel involved in the decision to 
centralize the IND core and those who were hired as support personnel for the core. I 
selected the departmental leaders so I could understand why the centralization was 
implemented and understand the intended operational structure. I selected the 
administrative personnel so I could fully understand how the IND core is operating.  
Below is a description of the responsibilities associated with the participants I selected 
for the interview protocol.  
 Participant 001 was a member of the AHC for about five years prior to moving on 
to a new position. While he was at the AHC his responsibilities varied. He was hired to 
oversee the administrative aspects of research, as well as assist with laboratory duties. 
Soon after his hire date, his duties were extended to administrative support for the IND 
core. 
 Participant 002 has been a staff member of the department since 2000. Her role in 
the department is to ensure regulatory compliance, assist Investigators in preparation of 
audits, and serve as a liaison between the department regulatory committees, and the IRB. 
 Participant 003 was a part of the department for about five years before moving 
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on to a different AHC. Along with numerous other tasks (clinical and research), he was 
charged with maintaining a senior leadership role within the IND core.  
 Participant 004 supports the IND core by writing the Chemistry, Manufacturing, 
and Control (CMC) sections of the IND application, supplies drug accountability, and 
manufactures the IND related Radio-pharmaceuticals. 
 Participant 005 has been with the University for nearly twenty-five years and is 
responsible for overseeing research within the department.  He assumed the role of 
Sponsor at the start of 2011.  
 I decided not to interview two groups of individuals from the background 
interview process: past Sponsor-Investigators, and personnel from OHR.  The first group 
includes four previous Sponsor-Investigators. I decided not to interview these four 
individuals because I did not believe they would be able to provide me with the specific 
reasons for centralizing INDs nor insight into the current operational structure of the core. 
While their input and perspectives of the core is valuable, I did not believe it was relevant 
to this capstone.  The data I am attempting to collect is to determine the operational 
effectiveness within the current centralized core.   
 The other group I will not interview personnel of OHR. The previous Director, 
who was involved with the development of the centralized office, is no longer an 
employee of the organization, and I did not have a way to contact this individual. The 
remaining individuals of OHR had limited involvement with the development and 
implementation of the core.  In addition, one individual was not employed with the 
organization at the time of implementation. I made the decision to exclude these 
individuals based on the above noted factors.  
41 
 
 
 
Interview protocol 
 I will use a seven-question structured interview process (Appendix A). There are 
six structured questions and one open-ended question which allow the participants to 
provide additional information about the history of the IND core.  The purpose of the 
background interviews is to gain an understanding of the history behind the development 
and implementation of the centralization. The content of the questions focuses on the 
following: the structure of INDs prior to centralization, when the idea was born, what the 
rationale was, who led the redesign, the vision of the centralized core, and the 
communication mechanisms used to inform Investigators of the change.  
 Question one: Can you provide information on the operational structure of the 
IND core prior to the implementation of the centralized model? I framed the first question 
to learn about the operational structure of IND related research within the department 
prior to centralization. I wanted to hear from the core members how they perceived the 
way in which decentralization was operating. My hope with these responses is to 
determine how the IND related protocols were managed prior to centralization.  
 Question two: When did the idea of a centralized IND core come about? This 
question is designed to learn when the idea was first born. I want to learn of the time 
period for this thought process.  
 Question three: What was the rationale for creating a centralized IND core? The 
third question is designed to learn what caused the department to change to a centralized 
structure.  
 Question four: Who led the re-design of the IND core? The fourth question is 
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designed to gain insight as to whether the leader of the redesign was an individual or 
group. 
 Question five: How did you envision the operational structure of the centralized 
IND core? The fifth question is designed to learn the intended structure of the 
centralization. I would like to understand how the leader (and those selected to be 
members of the core) planned to manage the associated responsibilities of a centralized 
service. 
 Question six: What mechanism(s) did you use to inform Investigators throughout 
the University of the Re-design of the IND core? The sixth question is designed to learn 
what mechanism was used to inform previous (and future) Sponsor-Investigators of the 
planned centralized core. With these responses, I intend to gain an understanding of how 
individuals were informed of the new process.  
 Question seven: Is there additional information about the background 
development of the IND core that has not been discussed so far in this interview? The 
seventh question is designed to be open-ended and allow the participant to provide 
additional information about the background of the core.  
 I will contact each participant via email requesting their participation in the 
interview. After agreement to participate, I plan to schedule private individual interviews 
with the five participants. I will meet with three of the participants in person, and two on 
the telephone due to distance. At the beginning of each interview, I will remind each 
participant that their participation is voluntary and the interview will be stopped at any 
time if they feel uncomfortable.   
 I will take extensive hand-written notes during the interviews. These notes will 
43 
 
 
include documentation of responses, observation of tone, and body language. At the 
conclusion of each interview I will write some field notes which will include my thoughts 
and feelings about the interview.  
Current state interviews 
 In order to fully evaluate the effectiveness of the centralized IND core, I will 
conduct in-depth interviews with three current staff members of the IND core as well as 
one external member. I selected the administrative manager, the sponsor's authorized-
representative and the cyclotron production manager for participation in these interviews. 
I selected these individuals as their roles keep the core functioning. 
 There are three groups that will not be interviewed for this capstone: Radiologists, 
Investigators using the core, and administrative staff of OHR. I decided to exclude these 
groups for a variety of reasons, but mainly because their involvement with the core is 
limited. The Radiologists are called upon to provide scientific input for drugs that are 
new to the core. A new IND has not been written or submitted within the last two years 
therefore, their expertise has not been needed often. They are responsible for 
collaborating with non-departmental Investigators on the conduct of the radio-
pharmaceutical component of the protocol, as well as for administering the radio-
pharmaceutical. I selectively excluded this group; they are indirectly involved with the 
aspects of the core.  
 The second group I decided not to interview for this capstone is Investigators and 
research staff who utilize the IND core services.  These individuals are valuable to our 
core as they request our services and keep the core running. To my knowledge, there has 
only been one complaint about the effectiveness of the centralized core. The complaint 
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was duplicate efforts were occurring. The Investigator held an IND for a separate drug 
(one not produced by this department). Since this was the only complaint I am aware of, I 
did not believe interviewing Investigators would provide much useful information for the 
purposes of my data collection. Their opinions and comments are valuable however; the 
focus of my data collection is on the internal infrastructure of the core. 
 Administrative personnel from OHR were not interviewed as well. I decided to 
exclude these individuals because their expertise is needed if the members of our core 
need assistance with regulatory guidelines. These individuals are not a part of the daily 
operations or infrastructure of the core.  Due to their limited involvement I will not 
include this group in the interview process.  
Interview protocol 
 There are ten questions included in this current state interview protocol (Appendix 
B). Of the ten, seven questions are open-ended as I want to investigate my underlying 
assumptions. The remaining three questions are close-ended questions.  If I feel 
additional information is needed at the time of the interview, I will ask the participant to 
elaborate on their response.  The content of the questions is centered on the current 
operational structure of the core. Because the purpose of these interviews is to hear from 
each key member their perspective on the current state and learn if they are aware of a 
future plan for growth, the questions are framed to facilitate my understanding of each 
participant’s perception. 
 Question one: can you give me an example of what is working well about the IND 
core? This question uses an appreciative inquiry type format. I would like to hear from 
each key member their view about the strength of the core.  
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 Question two: How would you describe your role within the IND core?  This 
question is designed to ask each participant their role in the core. I want to understand 
how they view their role in the core, as well as their role with the other core members. 
The purpose of the question is to confirm or disprove my hypothesis that the core is not 
operating in the way it was structured to operate.  
 Question three: Can you provide information on the current operational structure 
of the IND core?  This question is designed to learn from each participant the current 
operational structure of the core. My intention with this question is to learn more of the 
daily operations from the perspective of each participant.  
 Question four: What is the mission of the IND core? This question is designed to 
learn how each participant views the mission of the core. The purpose of this question is 
to determine if the perceived mission is viewed similarly among all participants.  
 Question five: Is the IND core satisfying all responsibilities associated with the 
role of Sponsor? This question is designed to learn if the core is satisfying all 
responsibilities. The intent with this question is to determine if each participant is aware 
of unfulfilled responsibilities.  
 Question six is: What are the number of INDs currently active under the core? 
What are the number of protocols currently active under the core? This is designed to 
determine if each member is aware of the number of IND's and protocols being held 
within the core. The purpose of this question is to determine if each participant is aware 
of how the core has grown over the past few years.  
 Questions seven: Do you have a limit on the number of INDs and/or protocols 
your core will support?  and question eight: How do you plan to handle management of 
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additional INDs/protocols? These questions are designed to learn about the projected 
future of the core. My goal with these two questions is to determine two things: if the 
core has set a limit on the number of INDs and/or protocols it will manage, and if plans 
are being developed for the future of the core.  
 Question nine: What mechanism(s) are currently in place to inform potential 
Investigators of your core? This question is designed to learn about the communication 
mechanisms (or lack of) in place to notify potential Investigators of the services. I want to 
know if there is an effective process in place to inform Investigators of the core services. 
The purpose of this question is to learn more from each participant of the structure. 
 Question ten: Is there additional information about the IND core that has not been 
discussed so far in this interview that you would like to add? The purpose of question ten 
is to allow the participant to provide additional information that was not covered in the 
above structured interview questions.  
 I will contact each participant via email informing them of the purpose of this 
capstone and requesting their participation in the interview process. I plan to conduct in-
person interviews in a private office within the department. All participants are 
employees of the organization and should be available to meet in person.  
 At the beginning of the interview, I will remind each participant of their right as a 
participant and the plan for maintaining confidentiality.  I plan to record each interview 
with a tape recorder and document the responses to each question on paper, and include 
observations of tone, and body language.  At the conclusion of each interview, I will 
document my thoughts and feelings from the interview.  
Confidentiality 
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 In order to maintain privacy of the participants involved in the interviews, all 
identifiable information (organization name and location, participant names, and titles) 
has been removed from this capstone.  The organization has been assigned a fictional 
name, and each participant has been assigned a unique participant ID number.  
 The documented notes and tape records will be stored in a secure cabinet outside 
of the office. The purpose for securing these documents is to maximize the participant’s 
privacy. At the completion of this capstone (November 2012), the notes and tape 
recordings will be destroyed.  
Other information 
 In addition to conducting interviews, I examined multiple documents relevant to 
the IND core (Appendix D). I reviewed and compared audit reports pre and post 
centralization.  In addition, job descriptions of the IND core manager, and 
correspondences with the FDA of the change in Sponsorship were reviewed.  
My role 
 My role within this capstone is two-fold: participant and observer. I have been a 
member of the organization for ten years and spent the past two years as an active 
participant in the IND core.  My role within the core is to oversee and assist with building 
the operational structure and supervise one of the staff members. My direct supervisor is 
one of the interviewees and the others are colleagues that I have worked with for the past 
ten years.  
  Due to my leadership role within the core, I am involved in the daily operations 
and responsible for promoting the mission of the core, as well as finding ways to remove 
barriers for my staff and other members of the core.  
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 Throughout my two years leading this core, I have often observed ways in which 
the structure of the core is flawed. I stepped into the position without fully understanding 
the level of complexity involved with the role of a Sponsor and did not have a clear 
understanding of each individual's role within the core. Soon after my involvement 
began, I hired the IND manager with a narrow understanding of the number of tasks 
associated with the role of core manager.  
 Over the past two years, I have listened to and dealt with numerous complaints 
and concerns from the staff about the operations within the IND core. These complaints 
included: not fully understanding their role, feelings of being overwhelmed by the 
number of tasks associated with job functions, and feeling unsupported by senior 
leadership. 
 In addition, I have observed a lack of monitoring protocols. Monitoring is one 
responsibility associated with being a Sponsor. . As described in Chapter 2, the Sponsor is 
responsible for monitoring research protocols conducted under an IND. The lack of 
monitoring has often been discussed among all staff members over the past two years.  
 These frustrations and concerns of the staff members have left me feeling 
helpless. As the Operations manager, I do not believe I am giving them the support and 
direction they need to feel successful in their roles. About a year ago, I made the decision 
to perform an organizational diagnosis of the core and determine the root cause of the 
problem.  
Controlling for bias 
 “Reducing diagnostic bias should begin with an understanding of its cause” 
(Armenakis, Mossholder, and Harris, 1990, p.563). As an insider of the core, I need to be 
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aware of things that can cause me to have a narrow perception of the ineffectiveness of 
the core.  There are a few factors that may cause bias in this capstone. The first is, I have 
been an employee with the department for ten years and indirectly heard stories about the 
implementation of the core.  The second way bias may be present in this capstone is my 
selection of participants and the third is my relationship with each participant. . 
  I always assumed the core was set-up as a result of hiring a new division chief. I 
based this assumption on previous off-line conversations I have had with members of the 
department. In realizing this may not be the full story, I decided to incorporate 
background interviews into this capstone.  Understanding the history of creating and 
implementing the core from several key stakeholders within the department is important 
because it will provide me with knowledge of operations I was not aware of previously.  
In addition, I will cross reference these interviews with documentation describing the 
reason for implementation. Cross referencing will help eliminate bias as I will be 
checking against another source.  
 The second factor of bias is the selection of participants. I selected these 
participants based on my knowledge of their involvement with the core. The information 
I gather will be limited to the view of insiders. I wanted to gain a more global perspective 
of centralization by including members from the research support office, whom were 
involved in the development, but I was unable to do. The member who was involved in 
the centralization is no longer with the University and I was unable to get in contact with 
this individual.  I tried to control bias by evaluating the role of each participant and 
reviewed previous documents outlining personnel within the core.  
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 The third factor of bias is my relationship with each participant I will interview 
for the current state of the core. Over the past two years, I have had many discussions 
with each of these participants; I may have a predetermined mindset of how they will 
answer each question asked. In order to minimize this, I will tape record each interview 
conducted. This will allow me the opportunity to spend time listening to the interviews 
prior to my data analysis and notice if there were points I missed.  
 My goal with the information I gather from this capstone is to determine the best 
way to improve the effectiveness of the core. In order to fully do this, I believe it is 
important to highlight all of the issues I may uncover. I do not want participants in these 
interviews to feel they could be the problem, based on their performance.  These 
participants may feel defensive and worry about the security of their job if these feelings 
arise. This concern may cause me to cover over some performance issues as I analyze my 
data. As you read this paper, I ask you to consider the following: 
• Did I miss specific history because non-departmental stakeholders were not 
interviewed?  
• Should I have interviewed a sampling (random) of Investigators who utilize the 
core?  
• Did I ignore performance issues of certain staff members? 
 In summary there are two sets of data collection for this diagnosis: background 
and current state. Both sets of interviews and review of relevant documentation will occur 
over the course of three months.  After all data is collected, I will review and analyze the 
results.  I will specifically look for themes throughout the data and confirm or disprove 
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the hypotheses outlined above. The results are presented in the next chapter.  
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CHAPTER 4 
 
RESULTS 
 
Data summary 
 In order to obtain the information to confirm or disprove my hypotheses, I 
conducted two sets of interviews: background and current state, and reviewed audit 
reports, job descriptions, regulatory files, and email communications. The data collection 
process was conducted over a total of eight weeks.  I will begin this section with the 
results of the background interviews and identify the themes which emerged during data 
collection.  Then, I will summarize the current state interviews and the themes which 
emerged. I will conclude this section with a summary of the data in relationship to my 
hypotheses. 
Summary of background interviews 
 I began the data collection process by conducting background interviews with 
several key stakeholders within the organization. The background interviews were 
conducted over a course of four weeks. The purpose of these interviews was to learn the 
rationale of creating a centralized IND core and to determine if clear objectives were 
developed for the operational structure of the core. As described in the methodology 
section of the paper, I selected individuals with active roles within the core to participate 
in the interview process. My goals for selecting these individuals were to understand the 
decision process for centralization and learn about the perception of those who were 
charged with outlining the infrastructure of the core, as well as those who were managing 
the core in its infancy. I contacted each individual via email requesting their participation 
in the interview. Details of the purpose of the interview and capstone topic were included 
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in the body of the email and I asked if they were willing to participate. Confidentiality 
and privacy were assured. As a result, participant's names and titles have been removed 
and the interviewees have been randomly assigned numbers ranging from 001-006.  
Potential participants were requested to respond directly to me via email with their 
decision. All five participants responded quickly with their willingness and desire to 
participate in the background interview process 
 
 The data collected from conducting the background interviews included the 
opinions of staff members about the history influencing the development and 
implementation of a centralized IND core. Five individuals were interviewed on the basis 
of their role within the core at the time of implementation.  Three of these interviews 
were conducted in person while two were conducted via telephone.  The results of the 
interviews are presented below in relationship to each question asked.  
 
 Question number one: Can you provide me with information on the operational 
structure of the IND core prior to implementation of the centralized model? The 
responses given by all participants were very similar. "There was no structure prior to the 
centralization" was the statement made by four of five participants. INDs could be held 
by Investigators, allowing them to take on the added responsibility of a Sponsor 
(Sponsor-Investigator). One participant even went as far as to describe the structure as a 
"free for all.”  Another participant named two individuals in the department that often 
filled the role of Sponsor-Investigator.  
 Question number two: When did the idea of a centralized core come about?  One 
participant was able to provide me with the specific time frame that the idea of 
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centralizing was discussed—September 2006.  The other participants were not clear on 
the specific time frame, but seemed to have an idea it was around 2006/2007. Two 
participants explained the idea came about as a response to non-compliance.  This date 
correlated with the time frame provided by the participants and documents within the 
core.  I cross-checked the dates with reports of the audit findings.  
 Question number three: What was the rationale for creating a centralized core?  
Through the responses to this question I learned about a significant tragic event within 
the AHC, which led to the redesign of the IND model within Department A. All 
interviewees identified non-compliance as the major reason.  One participant explained 
“the rationale for creating the core was for efficiency, to minimize errors, and quality 
control. In addition, the core was developed to prioritize the importance of specific 
INDs.”  Another participant specifically stated “the idea came about after OHR audited 
IND related protocols. Leadership of the AHC decided to implement a centralized office 
and asked Department A to be the pilot.” A third participant stated “senior leadership at 
the AHC approached senior leadership within Department A with the problem of non-
compliance and asked them to determine the best solution. With that, Department A 
decided it was best to implement a centralized office.”  
 Two participants provided a more thorough background as the reason the core was 
developed and implemented. Jessie Gelsinger’s case - - death of a research participant in 
a gene therapy trial-- was the primary factor in the structure change of managing INDs. 
This incident occurred in September 1999. The death of this research participant put the 
University in the spotlight throughout the research community. 
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 The death of this research participant sparked changes throughout the AHC. While 
many individuals may not see this at a national level, the changes are noticeable at the 
AHC. Shortly after the tragic incident, the AHC developed OHR, a centralized office to 
oversee the conduct of human research. One of the goals of this office was to audit all 
research protocols considered high risk.  “The AHC addressed the problem head-on and 
took aggressive steps to create and implement the Office of Human Research.” (Zhou, J, 
2003) The members of OHR took their roles very seriously and began developing a 
process for auditing high risk protocols.  
 Department A was one of a few departments throughout the University with high 
risk protocols--protocols using non-FDA approved agents-- and a production facility. 
Compliance issues were noted on eight protocols. OHR personnel shared their findings 
with departmental senior leadership and requested they implement a corrective action 
plan. Senior leadership agreed upon a centralized model to control compliance. "One 
participant noted the additional reasons behind centralization were to improve efficiency, 
and quality control.” 
 Question number four: Who led the redesign of the core? The responses from the 
participants varied. Two of five participants identified two groups involved in the 
development of the centralized core: senior leadership from OHR and senior leadership 
from Department A.  One participant indicated the Compliance Director within the 
department was also included. Another participant also indicated the newly appointed 
authorizing representative was involved in the redesign as well. One participant was not 
sure who was involved in the redesign of the core.  
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 Question number five: How did you envision the structure of the IND core? This 
question was designed to learn how each member imagined the core would operate. The 
responses had a mix of similarities and differences. One participant responded with “I can 
tell you my ideal vision, but I will tell you my vision based on the resources provided by 
the AHC. My vision was to build an organized regulatory submission process between 
Investigators, the core, and the FDA. This was the only thing the centralized core could 
handle with the limited resources.”  Another participant explained “I hoped the core 
would limit the number of active INDs and protocols.  I imagined there would be more 
resources.” A third participant stated “Not much changed from my perspective.”  The 
remaining two participants had similar responses. They both indicated they imagined the 
core as being one single point person to manage all regulatory responsibilities and 
monitoring.  
 Question number six: What mechanism did you use to inform Investigators of the 
redesign of the core? All five participants were uncertain of the exact method of 
notification. Two stated they were unsure, two thought the Investigators were notified via 
email, and another participant thought the notification was announced at a departmental 
research meeting and then disseminated to collaborators.  
 Question number seven: Do you have any other additional information you would 
like to share? Four out of five participants responded with “no. I do not have any 
additional information.” One participant added their opinion on the positives and 
negatives to centralization. The participant stated “The disadvantage to a centralized 
model is the lack of expertise per radio-pharmaceutical. In a decentralized system, the 
Sponsor-Investigator has all of the knowledge needed to run the protocol.”  
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Follow up questions 
 I did not ask follow up questions during the background interview portion of this 
diagnosis.  
Current state interviews  
 The second set of interviews I conducted was with four of the staff members of 
the IND core.  These interviews were conducted over the course of two weeks. My goal 
with selecting these participants was to gain insight about their perception of the 
operational structure of the core. I emailed each staff member informing them of the 
purpose of this thesis and requested their participation in the interview process. I 
contacted each individual via email requesting their participation in the interview. Details 
of the purpose of the interview and capstone topic were included in the body of the email 
and I asked if they were willing to participate. Confidentiality and privacy were assured. 
Each participant responded within twenty-four hours to my request and agreed to 
participate. The purpose of these interviews was to gather data relevant to the current 
operational state of the core.  I asked participants 004, 005, and 006 the specific questions 
outlined in appendix B.  Questions one through seven were focused on the current 
function of the core; while, question eight was structured to collect data on the plan for 
the future. I modified the questions for the interview with participant 002 (see Appendix 
C).  I made the decision to do this based on my understanding of their indirect role with 
the core at this time.  
 I began the interviews with an appreciative inquiry question. I did this so I could 
learn from these participants what they find is working well and to hear positive 
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feedback. Question number one: Can you give me an example of what is working well 
about the IND core? All four participants provided positive feedback to this question. 
Three participants described the communication with Investigators to be working well, as 
well as document management. One participant included the coordination between the 
Investigator and FDA is also working well. Some of the examples given by the 
participants include: “documentation of drug accountability seems to be running 
smoothly.” Another participant stated “It seems as if our documentation is well organized, 
our communication with the FDA is going well, and we are reaching out to Investigators 
to assist them.”   A third participant stated “The electronic files have been setup; 
communication with study teams is going well. We are starting to get protocols before 
they are submitted to the IRB for review.”The fourth participant explained “We now have 
a point person for maintaining INDs, tracking information necessary for annual review of 
the INDs, compiling information and training.”  
 Question number two: How would you describe your role within the IND core? 
Each participant responded with how they view their role within the IND core.  
Participant 005 chuckled and responded “Right now to try and stay out of people's way. 
My role is a high level voice to ensure the key vision of the office is being executed. The 
details of how that happens, I rely on the people on the ground to do.” Participant 006 
responded “I am the core.  I do everything. I handle the submissions, communication 
between the study teams, the cyclotron, and the Nuclear Medicine Physicians. I maintain 
the files. I do everything. The only thing I do not do is scientifically review the protocols, 
but nobody does that.”  Participant 004 responded “My responsibilities are clearly having 
to do with preparation of the CMC section for submission and scheduling the tracer for 
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research participants.” Participant 002 chuckled when I asked what her role within the 
core was. She responded “Supporting performer. At this point, I am trying to pull together 
a lot of the missing information for the INDs that were open prior to centralization.”  
 Question number three: Can you provide information on the current operational 
structure of the IND core? Three of four participants were asked this question. All three 
responded with their view of the core operations. Participant 004 described the core as 
being lopsided. He stated “Some things run smoothly. There needs to be higher level 
oversight.” Participant 005 described the core structure as being pretty simple. “There is a 
single person who runs the core with oversight from operations, collaborative support 
from compliance; the compliance manager is important to provide regulatory expertise. 
The core manager also has scientific support from physicians in the department. Part of 
the core manager's job is to understand what is needed and to effectively reach out to 
these various people.” Participant 006 responded with a detailed overview of the process 
from protocol initiation through start up. “An investigator usually contacts a Nuclear 
Medicine physician and then the protocol goes to Radiation Safety and PET Ops for 
review. The Nuclear Medicine physician is supposed to review the protocol and represent 
the study team. I personally do not believe some of them review the full protocol. 
Somewhere along the line I get involved, usually after all that has happened. Which 
shouldn't be --I should be involved from the beginning. I review the protocol and send 
emails to the study team about the process of electronic file setup, protocol setup (if 
applicable). If they do not have a proper protocol, I do work with them to develop it. 
Then everything gets submitted to the IRB. Once it is approved by the IRB, I submit the 
protocol to the FDA. After that I work with the coordinators – if they have one-- on 
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conducting a protocol under the IND office.  
 Participant 006 also added “About fifty percent of the time these Investigators do 
not have Coordinators. Or if they do, they are overworked or have never done this type of 
research before.” 
  Question number four: What is the mission of the IND core? A mixture of 
responses was given to this question by three of four participants. One participant was not 
asked this question. One participant described the mission as being a support for 
Investigators. Participant 004 explained “the overall vision was to have one place where 
all radio-pharmaceuticals were managed. This made sense for the cyclotron facility. 
However, there was and still is insufficient regulatory oversight when the centralized core 
was implemented. We need some type of regulatory office or auditor that is very hands on 
and present to work with each group of the core.”  A third participant explained “I kind of 
feel like the idea is very good. It is good to have a centralized office that provides all of 
the services needed for these Investigators to do their research. It is also good for outside 
groups.  The thing that went wrong with the mission is it wasn't properly thought out.  
There is no business plan and it's impossible to do all of the things that need to be done 
properly.”  
 Question number five: Is the IND core satisfying all responsibilities associated 
with the role of Sponsor? All four participants responded “no” to this question. I then 
followed-up by asking all four participants which responsibilities are not being fulfilled 
and why. Three of four participants described monitoring as the one responsibility not 
being fulfilled and believed the reason was due to the lack of resources. One participant 
explained training is also a responsibility not being satisfied by the core. Another 
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participant answered this question by stating there is a lack of high level oversight of the 
core.  A variety of responses were received when participants described the reason why 
the core is not satisfying all responsibilities. Two participants explained there is a lack of 
resources to support the responsibilities and one participant stated there needs to be 
regulatory support for the core. Participant 002 stated “We are trying, but not full there 
yet. We need to be able to provide all of the services associated with being a Sponsor. We 
need monitoring, collection of data on a regular basis. Collecting the data regularly may 
make the annual report submissions easier.” Participant 006 responded “you need more 
than superficial oversight. You need a separate monitor that goes out on a regular basis, 
who has a good rapport with the group. This person would also train the site staff.”  
Participant 005 stated “we need a strategy for monitoring. Right now, we have a semi-
strategy: auditing by OHR and monitoring by the PET center and the IRB. We need to 
come up with an explicit vision and plan for how the core will monitor. Maybe the plan is 
to allow those groups to do the monitoring and find a way to coordinate our actives with 
those groups and obtain the appropriate documentation.”             
 Question number six: What is the number of INDs currently active under the 
core? What are the numbers of protocols currently active under the core?  Three 
participants were asked this question. One participant was not able to answer and two 
participants, who are involved in the daily operations, were able to answer with 
explaining there are ten active INDs, and thirteen protocols under the IND core.  
 Question number seven: Do you have a limit on the number of INDs and/or 
protocols your core will support? This question was asked to three of four participants.  
Three different responses were received. Participant 005 explained “It depends on the 
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research. Everything should be driven by the research. If INDs are active and being used 
and people are doing research, I would continue to keep them open. That is the purpose 
of the office.”  Participant 006 stated in a tone of laughter “apparently not. There should 
not be a limit, but there should be more staff to provide the service. We are not providing 
the service. We are basically treading water and trying to keep our heads above it. “  
 Question number eight: How do you plan to handle management of additional 
INDs/protocols? This question was not clearly answered. Participant two answered “I 
think this is an executive type decision. From my perspective the cyclotron is 
underutilized. We can support more.” Participant 005 explained “The office should grow 
with the interest of the community. And evolve its thinking with work flow and processes 
to support. I do not have a preset on the number of INDs we will support. “Participant 
006 answered “I have no idea. If it keeps growing the way it is, I cannot manage it.   
 Question number nine: What mechanism(s) are currently in place to inform 
potential Investigators of your core?  This question was asked of three of four 
participants. Similar responses were received. Three participants answered “word of 
mouth is the communication mechanism.” Two participants responded “the addition of a 
website will be used as a communication tool.” Participant 002 explained “this is a big 
gap for me.  I do not have much communication with Investigators. These discussions 
usually occur between the Investigator and Nuclear Medicine Radiologist. I hope I 
become more involved in preliminary discussions with Investigators.” Participant 005 
stated “there is information on the web page we are developing. It will be mentioned at 
our annual research retreat.  A lot of it comes from people who want to do this work and 
they start to ask questions and we direct them to the core.  Participant 006 explained 
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“basically right now it is just word of mouth. I plan to do a website, but my biggest fear is 
making a website and getting more work.”  
 Question number ten: Is there additional information about the IND core that has 
not been discussed so far in this interview that you would like to add? All four 
participants were asked this question. One participant answered with “no. I do not have 
additional information to add.” Three participants answered with some feedback. 
Participant 002 said “we still need to establish a point where we will close out an IND. 
We should be encouraging Investigators to close out older protocols and move forward. 
When it comes to an FDA inspection, we want to make sure we can provide good 
records.” Participant 004 explained “It would really help the core if there was more 
regulatory oversight.”  Participant 006 responded “I think the idea of a core is a really 
great idea. I enjoy the work. There just isn't enough time to provide everyone with the 
service.  Not having the time I need makes me feel I am not doing my job well enough. I 
know that I am doing a good job with what I have to work with but, it's still that added 
stress of at the end of the week not getting to everything that needs to be done. “ 
Additional questions for participant 002 
 Additional question one: How often are you contacted by the IND core staff for 
your services/expertise?  "Yes, it depends on what is going on. At some points the IND 
core manager and I may talk two or three times a day if there is a particular issue. But at 
other times we may speak once a month. “ 
 Additional question number two: Do you meet often with the IND core? If yes, 
how often?  “Yes. I was attending meetings with the IND core manager and OHR, but I 
have not been included in recent meetings with them.” 
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Additional question number three: Do you believe the centralization has helped 
with compliance issues within the department?  “Yes. At least it has standardized what is 
required of Investigators. It has brought everyone to the same level whether they are an 
external Investigator or an internal Investigator. We can now lay down the law and inform 
Investigators what needs to be done. But, we still need more staff to provide better 
service to help them. It all comes down to needing more resources.”  
Follow-up questions 
 I asked some follow-up questions during interviewers with participants 004 and 
006. 
 Participant 004 was asked two follow-up questions in response to their response 
to questions number two and ten.  
 Follow-up question: Who currently completes the IND package? “I am not sure. 
In the past, the Sponsor and Core manager completed those sections of the IND. We 
haven't submitted a new IND in several years.  We are in the process of working on three 
new INDs, but I'm not clear on who is responsible for coordinating the activities.” 
 Follow-up question: Do you think your role within the core will change in the 
future?  “I hope it will. I hope the cyclotron will be included more in discussion, 
especially beginning decisions. Investigators need to understand the cyclotron will fail 
sometimes. The chemistry can be very complicated. There is a false sense of security. The 
nature of this area is trace chemistry. There are tiny amounts of things interacting. 
Sometimes things do not work right.”  
 Participant 006 was asked several follow-up questions in response to the answers 
they provided to questions two, three, five, eight and nine. I asked these additional 
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questions to learn more about their perspective on their responsibilities within the core 
and to determine if they feel they are being supported by others.  
 Follow-up question: So, nobody reviews the protocol?  Participant 006 responded 
“PET Ops looks for operational stuff. The IRB looks for safety. Nobody reviews to 
determine if it is a good protocol.”   
 Follow-up question: If an IND is already established, is the work load less? 
Participant 006 responded “yes. If we have an IND, an Investigator will contact us and 
say they would like to have a protocol under an IND. If it is a new IND there is a lot more 
involved. An investigator plan needs to be completed. A lot more research is involved in 
doing this. This could take months to a year.” 
 Follow-up question: Are you involved with this? Participant 006 explained 
“Somewhat. Mostly the scientists are involved in this part. My main job is to put the 
package together and make sure it gets to the FDA.”  
 Follow-up question: Why do you not feel you are close to having a monitoring 
program? The participant responded “because we need more staff. For the amount of 
INDs we support, we should have one administrative person who provides oversight and 
management, two monitors, and have a system to support database setup. That's another 
thing; we have Investigators that do not have databases.”  
 Follow-up questions: Is there anyone else involved in the core? The participant 
responded “there is no one else involved in the core except for my immediate 
supervisor.” I then asked if the cyclotron manager or sponsor representative is involved 
and she responded “they are not really part of the core, they manage a portion of the work 
that needs to be done to develop the IND, but they are not a part of the daily activities of 
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the core. They are not a part of the day-to-day tasks of the core.” 
 Follow-up question: Do you think it will help if they or the sponsor-representative 
were more involved in the daily activities? She responded “it would help with some 
aspects, especially the scientific/medical because I am not a Physician. I don't really 
know the drug information as well as whether or not these protocols are scientifically 
justified. So, for that piece yes, it would help if those people were more involved.” 
 Follow-up question: In addition, as the core grows what would really help you to 
continue to build the success of the core? “Honestly, I do not think the core is going to 
grow unless we have more staff.” I probed more by saying “I mean in terms of you 
receiving more protocols. Things will still be coming in...” She responded to this by 
saying “Right. We'll get the protocol sent to the FDA, but we will not be providing the 
service to these Investigators that we should be.  I can compare this to a pharmaceutical 
company.  There is a monitor and project manager on each protocol and available at all 
times. In the current state of our IND core, we cannot provide that level of service 
because the manager does not feel she has the time to dedicate to knowing the protocol in 
depth.  That is not growing; it's just piling more work onto the core.” 
 Follow-up question: Do you feel you need more leadership from the core? 
Participant 006 said “yes, I would like to send the protocol to the leader, and know that it 
has been reviewed for all perspectives. Leadership can be a committee; it doesn't have to 
be one person.” 
 Follow-up question: What specific tasks would you like to continue doing? 
Participant 006 stated “my first choice would be to work more closely with the CRCs and 
Investigators on developing the protocols. It would be ideal if I could have someone else 
67 
 
 
handle the submission. I would also like to get into more of the monitoring stuff. My title 
is IND manager, and I feel those activities are a manager's role. The day-to-day collecting 
of logs and checking in with groups should be delegated. But, there is no one to delegate 
these tasks to.”  
Other information 
 In addition to conducting interviews, I examined multiple documents relevant to 
the IND core. I reviewed and compared audit reports pre and post centralization. The 
audits revealed a lack of proper document management, drug accountability and 
monitoring.  The reports did not indicate a lack of FDA communication. Annual reports 
and communications seemed to be up to par I draw this conclusion based on the audit 
reports. On the other hand, this left me wondering if there was some type of 
undocumented level of non-compliance. Unfortunately, I was not able to confirm or 
disprove that speculation.   Reviewing these documents provided me with information on 
the progress of the centralized IND core. It took some time, but the core has established 
successful document management systems and communication.  These documents 
support the theme of successful establishment of document management systems.  
 I reviewed the job descriptions of the IND core manager. This description was 
actually something I created in 2010 when looking to hire someone to fill the position. In 
hindsight, I realized the description is very general and does not provide enough detail on 
each task.  The description reads “The primary function of this position is to manage the 
IND Office located within the Radiology Department. The manager will be responsible 
for serving as a liaison between Investigators and the FDA, monitoring high risk 
protocols and communicating with studies requiring an IND.”  As I mentioned 
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previously, I did not know the specific functions of the core at the time I hired an 
individual to fill the position. This document does not support a specific theme, but was 
able to highlight the importance of clear job descriptions.  
 The third set of documents I examined were correspondences with the FDA about 
the change in Sponsorship. The letter was detailed and explained Department A has been 
identified as the sponsor and an individual within the department was assigned the role of 
authorized-representative.  
 Participant 002 provided a copy of a process document during the current state 
interview. The document included a description of communication with Investigators, 
deadlines for annual report submissions and a time line for developing the infrastructure 
of the core.  
 In summary, this chapter presented the data I collected throughout this diagnosis. 
As outlined in chapter three, all identified participants took place in this diagnosis. In the 
next chapter, I will analyze and discuss the results in depth.  
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CHAPTER 5 
 
DATA ANALYSIS 
 
Problem statement 
 The centralized IND core was developed and implemented to resolve non-
compliance issues among Sponsor-Investigators; however, non-compliance issues were 
still noted on audit reports after the implementation of the centralized IND core.  The 
centralized model was not fully implemented, nor fully staffed to operate in the way it 
was structured.    
 This chapter will present an overall analysis of the data I collected by conducting 
this diagnosis.  
History 
 “So it would be helpful to know certain things about an organization's past to 
understand its current behavior and to speculate about how it might behave in the future” 
(Kimberly & Bouchikhi, 1995, p.10).  I have been involved in the centralized IND core 
for about two and a half years with limited understanding of the history behind the core. I 
entered this position with the plan and goal to create an efficient and effective office. 
About a year ago, I realized I would not be able to attain my goal without a full 
understanding of the reason behind centralization. The IND core was established as a 
result of a tragic death of a research participant. The tragic death of the research 
participant at this specific AHC resulted in changes to the structure within a single 
department. This change is similar to reactions research authorities had in the past when 
tragic events occurred. As outlined in chapter one, several historical events led to 
implementation of regulations. It seems a tragic event must occur before regulations are 
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implemented to protect human subjects. I began this capstone with the mindset that a 
clear plan was not developed before the implementation of centralization.  One 
participant was able to provide me email communications and documents outlining the 
new protocol/IND process during the interview. When she provided me with these 
documents, I asked if she had a business plan or some type of similar document. She 
explained a business plan was supposed to be developed by the Director of OHR because 
the centralized model was supposed to be implemented throughout the AHC. 
Unfortunately, to her knowledge the plan was never developed and the centralized model 
was not executed throughout the AHC.  
Emerging themes 
 
Throughout the data collection process, several themes emerged.  These themes 
included:  
• Lack of clear goals defining the type of IND model  
• Lack of group development 
• Successful establishment of document management system and communication 
mechanisms with FDA and Investigators  
• Lack of regulatory support from leadership 
 
 The themes were highlighted throughout the interview process with the core staff 
members.  Some of these themes coincide with the literature review presented in chapter 
two of this paper.  I will discuss each theme in detail in the upcoming paragraphs.  
 The first theme, lack of clear goals, was represented by responses given about the 
mission of the IND core. The responses provided by the participants were varied and 
skewed. Two participants did not directly answer the question, but rather provided their 
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opinion on what is and is not working. Since this important point was not mentioned, it is 
possible that the staff on the ground is not aware of the goals set forth by the leader of the 
core. The leader of the core was interviewed for this project. The response from this 
individual provides a clearer, broader response then the other participants.  
 The second theme, lack of group development, emerged with the responses 
provided by each individual on the current operational structure of the core and their 
individual roles. The participants provided in-depth explanation of the current operational 
structure of the core; however, the responses were compartmentalized to each 
participant’s specific role within the core. Each participant provided a very descriptive 
explanation of how they view their role within the IND core. I validated these 
descriptions by checking the job descriptions of the staff members.  
 These responses led me to believe the core is functioning as specific task groups 
working somewhat independently of each other.  
 The third theme, successes of the core was established with the responses to the 
question, “what is working well with the core?”  t. Overall, the participants described the 
data management and communication with the FDA and Investigators as being successes 
of the core.  
 The fourth and unexpected theme, lack of regulatory leadership, was described by 
two of the participants during the current state interviews. Comments were made during 
the interview process that highlighted the frustrations and concerns felt by the 
administrative staff members. One participant even went on to say they do not know 
where to turn when they have questions or concerns. These comments, concerns and 
frustrations were noted and indicate there is a need for a clearer support system. 
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Individuals need to feel support from leadership to feel their job is valuable and the 
operations are running smoothly.  
 In chapter two, I presented a review of the literature related to underbounded 
systems. The lack of leadership was highlighted by staff members and appears to be a 
result of an underbounded system. Two individuals were highlighted as serving 
leadership roles within the core. “Authority relations in underbounded systems are 
typically fragmented and unclear. Instead of a single authority source to whom all must 
ultimately answer, there are multiple and/or none to whom some intermittently report” 
(Alderfer, 1980, p.271). This statement fits the data I have collected. Staff members of the 
IND core are unsure who is their ultimate leader and do not feel they are supported. In 
this case, I view the core as having several authorities: the Sponsor-representative, 
compliance manager and operations manager. Who is the ultimate decision maker? Is it 
the authorizing-representative? These questions still remain. As a staff member of the 
IND core, I have experienced my own uncertainly with the level of leadership and how I 
fit into the equation.  
 In addition, I believe communication problems are highlighted. Alderfer (1980) 
theorizes communication problems in underbounded systems occur in situations when 
people do not create links among each group/individual nor are the appropriate people 
identified (p.273). I believe the communication pattern and leadership are somewhat tied 
together. Leadership needs to identify the appropriate people of the core and establish 
appropriate lines of communication.  
Hypotheses 
 Hypothesis 1: The centralized model was set in place without clear objectives. 
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During the current state interviews I asked three of the four participants to define the 
mission of the core. The responses received were varied, yet all reflected a centralized 
location for INDs and support for Investigators. The participants did not elaborate on the 
level of support they do or should be providing to the Investigators. One participant 
described the core as being a centralized area for all radio-pharmaceuticals to be 
managed. Again, the level of management was not defined.  I am still left wondering 
what the exact objectives of the core are at this point. Is the core supposed to be a 
complete Sponsor or is the core supposed to be more of a support service to 
Investigators? Alderfer (1980) indicates to some extent organizational goals provide some 
source of reasonableness for organizations. Clarity of goals cannot be found in 
underbounded systems as easily as optimal systems (p.270).  
 During the background interviews I asked the participants to provide their 
perception of how they envisioned the operational structure of the core. The mixture of 
responses leads me to believe the staff was not clear about the goals of the core. Each 
person had their ideal vision for the core. While this is valid and acceptable, the staff and 
leader should have had the same opinion on the objectives of the core.  
  “Participants may experience their system as floundering without a sense of 
direction” (Alderfer, 1980, p.270).  During the current state interviews one participant 
said “Not having the time I need to do my job makes me feel I am not doing my job well 
enough. I know that I am doing a good job with what I have to work with but, it's still 
that added stress at the end of week of not getting to everything that needs to be done.” 
This statement, as well as the look of uncertainly on the participant's face, lends credence 
to this hypothesis. This individual seems to be overworked and bearing the weight of the 
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core on her shoulders and feeling as if she isn't sure how to move forward. The objectives 
of the core need to be clearly defined. I believe once the objectives are clearly defined, 
staff members will feel a more defined role within the core.  
Hypothesis 2: The IND core is not operating in the way it was structured to 
operate. The IND core was established to be a central Sponsor of radio-pharmaceutical 
related research protocols. I formulated this hypothesis based on my initial contact with 
the core. Initially, due to my limited knowledge of IND work, I assumed the core was 
only supposed to serve as the portal between the Investigator and the FDA.  I then 
learned one individual within the department was the Sponsor's authorized-representative 
for all IND related work; the department as a whole was defined as the Sponsor. Soon 
after my role within the core was established, I realized several responsibilities were not 
being fulfilled and were the responsibility of a Sponsor. I began to wonder why that was 
happening. I did not believe individuals were purposely neglecting their responsibilities.  
To evaluate this hypothesis, I asked participants during the background interviews 
to describe how they envisioned the operational structure of the core. All four participants 
provided overviews of how they saw the core operating. One participant even commented 
that his vision was altered due to the resources provided by the AHC. Two participants 
envisioned the core being a single individual to manage regulations and monitoring. One 
participant explained the vision of the core was to manage the submission process 
between Investigators and the FDA. Only a few responsibilities of a Sponsor are 
highlighted in these responses. Perhaps my question was not clear to the participants. I 
wanted to learn about all aspects of the core including: regulatory, monitoring, medical 
oversight, drug accountability, etc...The question still remains, how was the core 
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supposed to operate? 
I asked the same question during the current state interviews. Two of the 
participants were also interviewed during the background interviews, one participant was 
not. The responses were more detailed than those received during the background 
interviews.  Two participants described the structure as being a single individual 
managing the core. One participant stated the structure of the core is simple, as there is 
one person managing it. He continued to explain the core manager is responsible for 
collaborating with the various people around to support the core (examples: compliance, 
operations, and science). A second participant provided a very detailed explanation of the 
IND process. Within this description, she highlighted key individuals and groups as 
support to the core. Some of these groups were regulatory oversight groups that I did not 
include in the participation of this diagnosis.  It would be helpful to include these groups 
when discussing the future infrastructure of the core.  
Hypothesis 3: The IND core is understaffed and unable to fully carry out the level 
of responsibility associated with being a Sponsor. The IND core manager was labeled as 
the central person within the core, as well as the primary person for completing the 
majority of responsibilities associated with being a Sponsor.  Four participants were 
asked if the IND core is satisfying all responsibilities associated with being a Sponsor and 
the response by all was “no.” Two of these participants stated the reason all 
responsibilities are not being met is due to the limited resources and personnel within the 
core. Another participant stated a strategy needed to be developed for completing the 
monitoring task. He explained personnel outside of the core may be able to assist with 
this. The fourth participant again noted there needs to be a higher level of oversight.  
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The time commitment for each administrative task seems to be greater than the 
amount of time that can be given by one full time employee. Monitoring and training are 
two tasks being neglected due to limited resources. The question remains, does the core 
need to hire more personnel or can the current personnel be utilized more? During the 
current state interview process I asked each participant to describe their role within the 
core. Two participants defined their role and spoke about the same task. These 
dissuasions led me to believe if the roles and tasks were clearly defined within the group, 
there would be a more cohesive structure. Alderfer (1980) stated there tends to be unclear 
and conflicting role expectations in underbounded systems (p.272). There is some 
overlapping of roles within the core at this time. I gathered this based on the discussion 
with two of the participants. Two individuals stated they are responsible for obtaining 
documents prior to centralization. Who is ultimately the one responsible for this task?  
There are several responsibilities associated with being a Sponsor. These 
responsibilities can be divided up. One participant described the core as being one single 
contact to manage regulatory submissions. During the interview he stated this individual 
must know how to reach out for support from operations, compliance and the physicians.   
I found this statement to be clear, but I am left wondering if the IND core manager is 
aware of this operational piece. In addition, he did not mention the cyclotron manager, 
the one responsible for producing the drugs.  Why? I view this individual as having a 
specific role within the core.  
I believe in order to maximize the group, the positions of the individuals listed in 
the above paragraph need to be clearly identified to all.  
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Hypothesis 4: Future expansion was not included in the planning when the 
centralized model was implemented.  The core was established to support four INDs, and 
eight protocols. I was unable to locate a document describing a plan for the future of the 
core. During the current state interview process, I asked each participant if there is a plan 
to manage the future growth of the IND office. I received a variety of answers. I do not 
believe the future of the core has been discussed among the individuals within the core. 
Participant 005 provided a high level response. He explained the core should continue to 
grow and evolve with the expansion of clinical research.  He did not provide details, such 
as hiring more support personnel. I am able to validate this hypothesis with the absence 
of a future plan, and the unclear participant responses. The lack of plan and responses is 
enough to validate there has been little discussion in regards to the growth of the core.  
I was unable to locate literature specific to the lack of planning within AHCs and 
specifically to the field of clinical research. The lack of literature highlights the need to 
evaluate the programs established as a result of non-compliance. Evaluating existing 
programs will help understand if these programs are improving compliance within the 
clinical research field. In addition, I believe it would be beneficial to evaluate current 
systems within AHCs and determine methods to enhance compliance.  
Earlier within this paper, I mentioned I was not comfortable trying new plans 
within the IND core due to my limited involvement. I felt this way and continue to feel 
this way because I am not confident of my role and the amount of power I have to make 
necessary changes. I did not explore much of my role during this diagnosis.  My role is 
something I need to clarify with my boss in order to fully support changes within the 
core. On the contrary, I do feel more confident in the changes I can propose to leadership. 
78 
 
 
Completing this capstone and research has given me more knowledge and understanding 
of the system.  I would like to further expand upon this self-exploration with learning 
from leadership their vision for my role.  
In summary, the data I collected with this research validated the core was 
established without clear objectives and goals. This capstone demonstrates the 
importance of the need for clear objectives, goals and defined roles within the 
infrastructure. Establishing these aspects at the beginning will help lead to success and 
eliminate confusion.  
One thing I did not do within this diagnosis is fully explore the different model 
types of an IND core. I think it would have been valuable to ask more questions 
regarding the type of service the core leadership would hope to perform. I did ask 
questions that provided some data, but not enough to really know what model is best 
suited for this department.  This is an area worth exploring in the future. Overall, the data 
collected is valuable and will provide the leadership with a view of the current system.  
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CHAPTER 6 
CONCLUSION 
Recommendations/Feedback 
 This feedback is designed for the IND Sponsor-Representative. If he is interested 
in moving forward with a change management plan, I propose presenting this feedback to 
the IND core manager, cyclotron manager, regulatory manager and other indirect staff 
members of the core.  
 The centralized IND core was developed and implemented to resolve non-
compliance issues among Sponsor-Investigators; however, non-compliance issues were 
still noted on audit reports after the implementation of the centralized IND core.  The 
centralized model was not fully implemented, nor fully staffed to operate in the way it 
was structured.   Over the course of eight weeks, I collected and analyzed data to 
determine what is and is not working well with the centralized IND core.  I conducted 
interviews with six staff members and reviewed archival data. I conducted two types of 
interviews: background and current state. The background interviews included five staff 
members, and the purpose was to obtain the history and rationale for creating a 
centralized IND core. The current state interviews were designed to obtain information on 
the current structure and operations of the core. I interviewed four staff members. Prior to 
2007, Investigators wishing to conduct research protocols using a radio-pharmaceutical 
took on the role of Sponsor-Investigator. A death of a research participant led to an 
investigation of the conduct of research protocols throughout the AHC. The findings 
demonstrated non-compliance issues leading to the development of this centralized core. 
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At the time of implementation the core supported four INDs, and eight protocols.  
Why the problem exists  
 The centralized IND core is effectively serving as the communication portal 
between Investigators and the FDA, as well as maintaining organized regulatory files. 
These two areas have improved the level of compliance among Investigators conducting 
research with radio-pharmaceuticals.  Since its implementation, the core has grown to 
support ten INDs, and thirteen protocols, and has not grown in staff size.   
 At the time of implementation, the definition of roles and task assignments were 
not clearly defined other then the role of the IND core manager. The IND core manager 
job descriptions designated this individual as being responsible for managing the 
communication between Investigators and the FDA, document management, and 
monitoring. The IND core manager states she has been unable to attend to the monitoring 
task due to lack of time. However, she has recently been able to become engaged with 
this task and started monitoring protocols.  
 The IND core manager is responsible for about seventy-five percent of the 
Sponsor responsibilities. The remaining amount is completed by the cyclotron manager. 
Two responsibilities are not being fulfilled by the centralized core:  monitoring and 
Investigator/study team training. These responsibilities have not been assigned by the 
Sponsor-Representative.  Furthermore, the lack of fulfilling these responsibilities still 
categorizes the centralized core as being non-compliant.   
 There is a lack of role clarity of the operations manager, and compliance manager. 
There is little to no clear plan of how these individuals should be assisting with the daily 
tasks of the core.  Several participants described the other participants as oversight 
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personnel; however, the amount of involvement they have is unclear at this time. The 
members of the group meet one-on-one, yet there is a lack of standing group meetings 
where all members are present.  
 The core has doubled the amount of INDs since 2007. The core members have not 
addressed the growth nor discussed a plan for managing continued growth.  
Table 4. Feedback 
 
Category Responses  
1 Items working well   
Document management  4/4 
Communication with FDA 4/4 
Communication with Investigators and study teams 4/4 
Drug accountability  1/4 
2 Items to improve   
Monitoring 4/4 
Training 1/ 4 
Regulatory support 1/ 4 
Additional resources 3/ 4 
Discussion of future has not occurred 4/4 
 
End result if problems are not addressed 
 If clarification of roles is not provided, the tasks not assigned will continue to go 
left unassigned and the core will continue to be non-compliant. The lack of role definition 
will also continue to isolate and fragment individuals within the group.  
 The inter-group dynamics should be addressed as well. The IND core is made up 
of several working groups which, at some level need to work with each other to manage 
successful operations of the core as a whole system. If the issue of inter-group dynamics 
is not addressed, the groups will continue working independently, and without a clear 
purpose/mission. This in turn will not provide a full service support to Investigators 
wishing to conduct research with radio-pharmaceuticals.  
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 If the group does not discuss the plan for managing future growth of the core, 
IND applications will become backlogged, and the support to ensure compliance will 
decrease. Unfortunately, this could result in a tragic event and result in the shutdown of 
the department's research facility.  
Recommended solutions 
• Review the complete list of Sponsor responsibilities and group them into several 
categories 
• Administrative 
• IND application submissions 
• Annual reporting  
• Record management/retention 
• Ongoing monitoring  
• Drug manufacturing/shipping 
• Drug receipt/logging/dispensing 
• Regulatory training  
• Medical oversight 
• Sponsor's authorized-representative   
• medical expertise  
• assistance with trail design and oversight 
• Review the level of time commitment needed per task 
• Schedule a meeting to review data with the IND core staff members 
• Have an open discussion with the staff members to determine the best process for 
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managing the current workload 
Expected benefit 
 The expected benefit is to gain a sense of collaboration among the key members 
of the IND core and continue building the core to support IND related research. 
Other  
 I highlighted three questions of importance to me as I wrote the methodology 
chapter. These were questions I felt were worth answering at the conclusion of this 
diagnosis.  
• Did I miss specific history because non-departmental stakeholders were not 
interviewed?  As I conclude this diagnosis, I believe it would have been valuable 
to interview the individuals from ancillary departments for this paper. I believe 
these individuals could have offered more history into this paper.  
• Should I have interviewed a sampling (random) of Investigators who utilize the 
core? I believe interviewing Investigators utilizing the core would have been 
valuable. However, for the purpose of this paper, the results would not have 
supported my hypotheses.  
• Did I ignore performance issues of certain staff members? This is a somewhat 
difficult question to answer with the data I collected. It may have been worthwhile 
to evaluate the job descriptions of each participant I interviewed and add 
questions specific to each participant's role. At this point, I do not feel that would 
have been beneficial for this diagnosis. If measuring job performance is important 
to leadership, the roles need to be clearly defined first. Then, leadership can begin 
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to evaluate and measure job performance. At this time, I do not believe this point 
is relevant to the diagnosis.  
Future research  
 The biggest struggle with this capstone was searching for literature relevant to 
assessing clinical research programs within AHCs. Unfortunately, there is limited 
information publicly on the assessment of current structures and programs established as 
a reaction to tragic events over time. I believe it would be beneficial to the research 
community for further assessment of regulations and programs to be conducted. I believe 
assessing the current infrastructure could prevent tragedy from happening in the future. 
Why wait until there is another tragedy?  
 AHCs fit into the definition of underbounded systems. The system is 
decentralized, roles are not defined and the goals are not always clear.  I am not 
suggesting this system be changed, but rather we take the time to learn how to work 
within this system to produce solid research and minimize risk to study participants. 
Overall, the core was established to minimize non-compliance and offer support to 
Investigators. I think this concept is valuable and now we should take the opportunity to 
enhance it.  
Learnings  
 This capstone was a learning experience that provided me with knowledge I never 
expected. I wanted to use the skills and knowledge learned from this program to 
enhanced my professional skills in my current organization, as well as expand the 
infrastructure within my current organization. I decided to conduct an organizational 
diagnosis so I could learn what is and is not successful with the current setup of the IND 
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core and provide feedback to my supervisor.   I wanted to demonstrate the importance of 
understanding the dynamics at play. 
 When I first started working on the idea of conducting a diagnosis, I realized there 
were things from the past that shaped the centralization and I needed to learn about them 
before I could understand the current operational structure. I conducted a series of five 
interviews with staff members (past and present) to gain knowledge of the history 
through memories. In hindsight, it would have been valuable to include Investigators that 
were affected by the centralization. I would have been given a different perspective on 
the history.  
 During this process, I was provided with a document outlining the implementation 
plan. This document was created by a previous staff member, who did not provide this 
information at the time of interviewing nor during the transfer of responsibilities to the 
new IND core manager. Why was this document not offered before? The individual 
originally hired to serve as the IND core manager was asked to relinquish these 
responsibilities at the beginning of 2010.  To my knowledge, the reason this individual 
was replaced within the core was because the Sponsor files were not being managed 
appropriately. In order to improve compliance, the vice chair of research asked me to step 
in and improve the document management system.  I believe this transition may have 
caused anxiety and uncertainty with the previous staff member and left the core in a 
vulnerable place. This is one area that I did not explore within this capstone.   
 In addition, the leadership of the core changed in January 2011. The Sponsor-
Representative resigned and the responsibilities were reassigned to a senior level 
physician. The current Sponsor-Representative juggles several leadership positions within 
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the department. Leadership within the core is another theme that was highlighted 
throughout this process. Again, this was not an area I explored during this diagnosis. If 
time allowed, this would be an area worth exploring as I believe the change in personnel 
may have impacted the goals and group structure.  
 I was not able to explore the leadership of the core; however, this diagnosis 
showed the importance of understanding an organization's history, role definition, and 
inter-group dynamics. Regulations related to clinical research have been developed in 
response to tragic events. Understanding these events in-depth can mold the future of an 
organization. The IND core was centralized due to a tragic event within the AHC. Did 
centralizing enhance compliance amongst Investigators? The answer is, somewhat. There 
is still so much that needs to be improved. For example, building a core that can fully 
support all responsibilities associated with an IND Sponsor.  
 Roles need to be defined clearly with the development of infrastructure. This core 
can grow successfully if leadership is willing to redefine the roles and responsibilities of 
the core. This clarity will also enhance the dynamics and enable the group to function 
more as a whole group rather than subgroups.  This diagnosis has taught me a lot about 
the above, but also about myself. It has taught me that I should feel comfortable inquiring 
about the process, potential staff members and take the lead on defining a clear process. I 
believe if time is taken in the beginning to organize and establish a program, it will be 
successful.  
 During this process, I realized my role was much more than described.  I am not 
only there to supervise the IND core manager, but there to lend a hand or provide creative 
ideas.  I've tried my best to be a support to the IND core manager, but I haven't been 
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involved enough in the daily tasks to be a benefit. 
 This experience has been worthwhile and I would not change one piece of it. I 
learned how to conduct an organizational diagnosis from start to finish. An additional 
challenge was conducting this within the organization I am a part of currently. It took 
courage and strength to identify the problem and ask my colleagues for their 
participation. This experience has allowed me to grow professionally. I've had the 
opportunity to dedicate additional time to reviewing literature relevant to research 
regulations and other academic centers. An opportunity I did not pursue in the past. 
Furthermore, I had the opportunity to use my learnings from the Organizational 
Dynamics program and apply them to a real life situation. I was able to utilize my 
understanding of organizational diagnosis and apply it. In addition, this capstone allowed 
me to learn more about underbounded systems, the impact history has on organizations, 
and the purpose of planning. I have learned a great deal and am thankful for such an 
opportunity.  
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APPENDIX A 
BACKGROUND INTERVIEW QUESTIONS 
 
Introduction 
Thank you for agreeing to speak with me about the IND core.  
You are being invited to participate in this interview because you were a key stakeholder 
in the development of the centralized IND core.  Your participation is voluntary which 
means you can choose whether or not you want to participate.  Before I begin I would 
like to tell you a little bit about the purpose of this interview.  As part of my completion 
requirements for the Master’s of Science in Organizational Dynamics, I am required to 
complete a capstone. The focus of my capstone is to perform an organizational diagnosis 
of the IND core.  The purpose of this interview is to collect information regarding the 
background history and development of the centralized IND core.  
The interview will take about 60 minutes. You do not have to answer any questions you 
do not wish to answer and you may stop at any time.  I will maintain confidentiality 
throughout this interview and the writing process. Neither your name nor role will be 
identified. The information you provide in this interview will be identified by a 
participant ID. Would you like to continue with this interview?  
 
Background interview questionnaire 
 
• Can you provide information on the operational structure of the IND unit prior to 
the implementation of the centralized model?  
• What was the rationale for creating a centralized IND unit?  
• When did the idea of a centralized IND unit come about?  
• Who led the redesign of the IND unit?  
• How did you envision the operational structure of the centralized IND unit?  
• What mechanism(s) did you use to inform Investigators throughout the University 
of the Re-design of the IND unit?  
 
 
 
 
APPENDIX B 
CURRENT STATE INTERVIEWS 
Introduction 
Thank you for agreeing to speak with me about the IND core.  
You are being invited to participate in this interview because you are a key stakeholder in 
the IND core.  Your participation is voluntary which means you can choose whether or 
not you want to participate.  Before I begin I would like to tell you a little bit about the 
purpose of this interview.  As part of my completion requirements for the Master’s of 
Science in Organizational Dynamics, I am required to write a capstone. The focus of my 
capstone is to perform an organizational diagnosis of the IND core.  The purpose of this 
interview is to collect information regarding the current structure of the centralized IND 
core and to determine its effectiveness.   
The interview will take about 60 minutes.  I will keep what you tell me during the 
interview confidential.   Neither your name nor role will be identified in the capstone. 
The information you provide in this interview will be identified by a participant ID. Do 
you have any questions?  Would you like to continue with this interview?  
 
 
Interview questionnaire 
 
• Can you give me an example of what is working well about the IND core? 
• How would you describe your role within the IND core?  
• Can you provide information on the current operational structure of the IND core?  
• What is the mission of the IND core?  
• Is the IND core satisfying all responsibilities associated with the role of Sponsor?  
• If no, which responsibilities are not being fulfilled? And why do you 
believe they are not being fulfilled?  
• What is the number of INDs currently active under the core? What is the number 
of protocols currently active under the core?  
• Do you have a limit on the number of INDs and/or protocols your core will 
support?  
 
 
• How do you plan to handle management of additional INDs/protocols?  
• What mechanism(s) are currently in place to inform potential Investigators of 
your core?  
• Is there additional information about the IND core that has not been discussed so 
far in this interview that you would like to add?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX C 
CURRENT STATE INTERVIEW-PERIPHERAL MEMBER  
Introduction 
Thank you for agreeing to speak with me about the  IND core.  
You are being invited to participate in this interview because you  are a key stakeholder in 
the IND core.  Your participation is voluntary which means you can choose whether or 
not you want to participate.  Before I begin I would like to tell you a little bit about the 
purpose of this interview.  As part of my completion requirements for the Master’s of 
Science in Organizational Dynamics, I am required to write a capstone. The focus of my 
capstone is to perform an organizational diagnosis of the IND core.  The purpose of this 
interview is to collect information regarding the current structure of the centralized IND 
core and to determine its effectiveness.   
The interview will take about 60 minutes. Neither your name nor role will be identified in 
the capstone. The information you provide in this interview will be identified by a 
participant ID. Do you have any questions?  Would you like to continue with this 
interview?  
 
 
Interview questionnaire 
 
• Can you give me an example of what is working well about the IND core? 
• How would you describe your role within the IND core?  
• How often are you contacted by the IND core staff for your services/expertise?  
• Do you meet often with the staff?  
• If yes, how often? 
• If not, why not?  
 
 
 
 
 
 
 
 
APPENDIX D 
DOCUMENTS REVIEWED  
 
• Audit reports: pre and post centralization 
• Job description of current IND core manager  
• FDA correspondences  
Process document provided by participant 002 
 
